
STAGE 1 FINAL REPORT

January 11, 2013
## Contents

Introduction .................................................................................................................................................. 3

Two-Stage Consensus Development Process ............................................................................................... 4

Purpose ......................................................................................................................................................... 5

Concept Evaluation ....................................................................................................................................... 5

  Overarching Issues ................................................................................................................................. 5

Concept Evaluation Summary ....................................................................................................................... 8

  GU Concepts Recommended for Approval ........................................................................................... 9

  GI Concepts Recommended for Approval .............................................................................................. 21

  GU Concepts Not Recommended for Approval .................................................................................. 43

  GI Concepts Not Recommended for Approval .................................................................................... 55

Appendix A: Concept Specifications ........................................................................................................... 57

Appendix B: Project Steering Committee and NQF Staff ............................................................................ 81

Appendix C: Measures Endorsed in GI/GU since March 1, 2007 ................................................................. 83

Appendix D: Related Concepts & Measures ............................................................................................... 85
National Voluntary Consensus Standards:
Gastrointestinal and Genitourinary Endorsement
Maintenance: Two-Stage Pilot, 2012

STAGE 1 FINAL REPORT

Introduction

Gastrointestinal (GI) motility and functional bowel disorders (e.g., gastroesophageal reflux disease, gastroparesis, irritable bowel syndrome), comprise about 40% of the GI problems for which patients seek care and affect up to 25% of the US population. These disorders not only cause symptoms and pose a heavy burden of illness but also impact quality of life and work productivity. With such a high prevalence within the population, the financial burden of the treatment of GI disorders is also high and has been estimated at nearly $10 billion annually in direct costs, and $20 billion annually in indirect costs.

Similarly, genitourinary (GU) conditions, including urinary tract infections (UTI), cystitis, benign prostate hypertrophy (BPH), and urinary incontinence (UI) pose a heavy burden on quality of life and healthcare spending:

- In 2000, costs associated with evaluation and treatment of BPH cost were estimated at $1.1 billion annually.
- 8.27 million of the adult outpatient visits in 2000 (1.41 million men; 6.86 million women) were attributed to UTIs as the primary diagnosis with an estimated $3.5 billion expended for evaluation and treatment.
- In 2007, UI was estimated to affect 9-22 percent of U.S. adults with an estimated cost of $463.1 million expended annually for evaluation and treatment.

NQF has endorsed several consensus standards to evaluate the quality of care for topic areas related to gastrointestinal and genitourinary diseases over the last several years. As quality measurement has matured, better data systems have become available, electronic health records are closer to widespread adoption, and the demand for meaningful performance measures has prompted development of more sophisticated measures of healthcare processes and outcomes for gastrointestinal and genitourinary conditions. An evaluation of the NQF-endorsed® gastrointestinal and genitourinary measures and consideration of new measures will ensure the currency of NQF’s portfolio of voluntary consensus standards.


Two-Stage Consensus Development Process

This GI/GU measure endorsement project is a pilot of the proposed two-stage Consensus Development Process (CDP), which is consistent with but not identical to the NQF CDP version 1.9. In response to feedback from several developer organizations and stakeholders, this two-stage process was conceived based on the following premises:

- Provide the measure developer community with an opportunity to get early feedback on measures at the conceptual stage of development and the input of an expert Steering Committee on the importance criterion before significant resources have been invested in developing a fully-specified and tested measure;
- Provide an earlier opportunity to address harmonization concerns; and
- Enable greater flexibility for entering the measure evaluation process at different stages of measure development (i.e., conceptual stage, fully specified and tested)

This pilot began with the evaluation of concepts and measures against the importance criterion in stage one, including measures that are submitted with full specifications and testing and those undergoing maintenance. Measures with full specifications and completed testing that pass the importance criterion in the first stage will be further evaluated against the remaining criteria (scientific acceptability, usability, and feasibility) in stage two scheduled to begin in 2013. In addition to the scope of the evaluation, which is divided between the two stages, this two-stage differs from the current CDP (V1.9) in the following ways:

- **Technical review of concept/measure submissions is required:** NQF staff provides individualized support to any developer requiring assistance with the submission process. Each developer submitting concepts for review is required to submit a subset of their submission forms for technical review by NQF staff. Staff reviews these forms to ensure they are complete and responsive to the submission items.
- **NQF member pre-Steering Committee meeting comment period:** This two week comment period was open to NQF members to submit comments for consideration and discussion by the Committee at the in person meeting.
- **Steering Committee recommends “approval” of measure concepts:** Prior to “endorsement” of the measure as occurs in the current CDP, the Steering Committee makes recommendations for “approval” of concepts.
- **Developer checklists:** A checklist is provided to each developer following the Committee’s review and recommendations for concepts in stage one. Each checklist summarizes the Committee’s recommendations for improving the concept(s) and considerations for specifying and testing the measure that must be addressed prior to submission to stage two.
- **Up to 18 months for development of approved concepts:** Developers whose concepts approved in stage one, will have up to 18 months to fully develop, specify and test the measure before submitting it for stage two review against the remaining NQF criteria.
- **Stage one concludes with “approved concepts”**: Endorsement is not granted until a measure passes all four NQF criteria at the end of stage two.
- **No member voting period in stage one.**
- **No appeals period in stage one.**
All other steps and processes are consistent with the current CDP. This pilot project will be evaluated to determine strengths and weaknesses and opportunities for improvement throughout its course to help determine which changes to the current CDP will be fully implemented. The results of this process evaluation and recommendations for changes to the CDP will be addressed by the NQF Consensus Task Force.

**Purpose**

The purpose of this report is to summarize the review of the 18 measure concepts submitted to this project for evaluation against the Importance criterion. The evaluation, comments and feedback received during stage one of this project specifically related to the two-stage CDP process will be addressed in a separate effort and report.

**Concept Evaluation**

On August 27-28, the GI/GU Steering Committee met to evaluate 18 measure concepts submitted for evaluation against the importance criteria. The Steering Committee ultimately recommended 14 concepts for approval, 12 of which were subsequently approved by the Consensus Standards Approval Committee (CSAC) and the Board of Directors. A summary of each concept’s evaluation and recommendations throughout the process is captured in the evaluation tables beginning on page 8.

### GI/GU ENDORSEMENT MAINTENANCE, 2012 SUMMARY

<table>
<thead>
<tr>
<th></th>
<th>Maintenance</th>
<th>New</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concepts under consideration</td>
<td>6</td>
<td>12</td>
<td>18</td>
</tr>
<tr>
<td>Approved Concepts</td>
<td>6</td>
<td>6</td>
<td>12</td>
</tr>
<tr>
<td>Concepts Not Approved</td>
<td>0</td>
<td>6</td>
<td>6</td>
</tr>
</tbody>
</table>

**Overarching Issues**

**Evidence guidance**

Many of the measure submissions to this project did not include sufficient information on the quantity, quantity and consistency of the evidence supporting the measure focus. For example, referring to guidelines without the description of the underlying studies that support the guidelines made it difficult for the Committee to rate the evidence subcriterion as described by the NQF 2010 Evidence Task Force report. In July 2012, the Consensus Standards Approval Committee (CSAC) discussed the challenges of obtaining the underlying evidence in many of the current clinical guidelines. The CSAC decided that despite the heterogeneous state of guideline development, specifically this transparency of the evidence supporting guidelines, no change to the criterion was warranted and every effort should be made by the developers to provide the information needed by the Committee to evaluate the evidence subcriterion. If required, the experts on the Committee can supplement their knowledge of the evidence; however, it should be made clear when there is a lack of evidence cited by the developer to support the measure focus.
The information provided to the Committee for the GI/GU measures was quite variable in detail and responsiveness to the NQF criterion for the quantity, quality and consistency of the evidence. To provide greater transparency in the Committee voting “NO” for the evidence criterion, two “NO” voting options were given:

1. **No, evidence does not meet guidance for quantity, quality, consistency (including no empirical evidence exists)**

   If the Committee voted *No, evidence does not meet guidance for quantity, quality, consistency (including no empirical evidence exists)*, they were given an opportunity to invoke an exception to the evidence criterion by weighing the benefits and harms to using the measure despite the lack of specific evidence. If the Committee agreed, based on a majority vote, that the benefits outweighed the harms, the concept would continue in the evaluation process.

2. **No, insufficient information submitted to rate quantity, quality, consistency of body of evidence.**

   If the Committee voted *No, insufficient information submitted to rate quantity, quality, consistency of body of evidence*, they were given an opportunity discuss the body of evidence available based on their expert knowledge. If in the Committee’s expert opinion the body of evidence would meet the NQF’s criteria for quantity, quality, and consistency, the concept could continue in the evaluation process based on a majority vote.

**Consensus Standards Approval Committee (CSAC) Review**

The CSAC reviewed the concepts approved by the Steering Committee during their November 2012 in person meeting. Given this is a new process and it was the first opportunity for CSAC to review and approve concepts recommended by a steering committee, there was broad discussion on the process and the desired direction and preferences for concepts that will be NQF approved. The CSAC raised the following points for further discussion in stage two and for guidance on future concept submission and review:

- A distinction should be made between concepts for fully specified and maintenance measures and concepts for measures that have not been fully developed and tested.
- While process and structural measures are also needed to improve performance, outcome measures are most desirable. Concepts for non-outcome measures submitted for NQF approval should provide strong demonstration of proximity to outcomes via the evidence submission and/or rationale for why the desired outcome cannot be measured.
- **Steering Committee recommendations for improvements to concepts must be addressed by developers via the checklist when measures are submitted for stage two review. The checklist should be used to determine whether the necessary changes to the concepts have been made to the measure prior to stage two review.**

During review of concepts, the CSAC can disapprove of concepts recommended by the Committee based on concerns such as those related to cross cutting issues related to measure properties (i.e., lack of harmonization with the endorsed measure portfolio), lack of consensus across stakeholders, process
issues encountered during the review process, or lack of importance/added value to the endorsed measure portfolio. During this project the CSAC disapproved of two concepts recommended by the Committee based on their concerns with lack of evidence linking the concepts to outcomes and lack of importance to the overall measure portfolio.
Concept Evaluation Summary

GU Concepts Recommended for Approval

0030 Urinary Incontinence Management in Older Adults - a. Discussing urinary incontinence, b. Receiving urinary incontinence treatment – A patient reported measure .................................................. 9

0098 Urinary Incontinence: Assessment, Characterization, and Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older – an administrative measure ........................................................................ 12

C 2038 Performing vaginal apical suspension (uterosacral, iliococygeus, sacrospinous or sacral colpopexy) at the time of hysterectomy to address uterovaginal prolapse ............................................ 14

C 2052 Reduction of Complications through the use of Cystoscopy during Surgery for Stress Urinary Incontinence (SUI) ........................................................................................................ 16

C 2063 Use of cystoscopy concurrent with prolapse repair surgery ................................................................................. 19

GI Concepts Recommended for Approval

0622 GERD - Upper Gastrointestinal Study in Adults with Alarm Symptoms .................................................. 21

0635 Chronic Liver Disease - Hepatitis A Vaccination ......................................................................................... 24

0658 Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients .................................................................................................................. 26

0659 Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps- Avoidance of Inappropriate Use ............................................................... 28

C 2056 Colonoscopy Quality Index ......................................................................................................................... 31

C 2059 Inflammatory Bowel Disease (IBD) preventive care: corticosteroid sparing therapy ........................ 37

C 2065 Gastrointestinal Hemorrhage Mortality Rate (IQI #18) ........................................................................ 40

GU Concepts Not Recommended for Approval

C 2037 Objective characterization of pelvic organ prolapse prior to surgery .......................................................... 43

C 2049 Complete Workup for Assessment of Stress Urinary Incontinence (SUI) Prior to Surgery ........ 45

C 2050 Patient counseling on treatment options, including behavioral and surgical treatments prior to Stress Urinary Incontinence (SUI) surgery .................................................................................. 48

C 2051 Patients Counseled About Risks Associated with the Use of Mesh in Sling Surgery Prior to Surgery ........................................................................................................................................... 51

C 2054 Assessment of treatment within one year of Stress Urinary Incontinence (SUI) surgery ........ 53

GI Concepts Not Recommended for Approval

C 2062 Inflammatory Bowel Disease (IBD) preventive care: corticosteroid related iatrogenic injury – bone loss assessment ........................................................................................................... 55
GU Concepts Recommended for Approval

<table>
<thead>
<tr>
<th>Measure Concept Submission Form</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status:</strong> Maintenance, Original Endorsement: August 10, 2009</td>
</tr>
<tr>
<td><strong>Description:</strong> This is a patient-reported measure collected through the Health Outcomes Survey with two rates that address management of urinary incontinence in older adults. Discussing urinary incontinence: Percentage of patients 65 years of age and older who self-report having a urine leakage problem in the last six months and who discussed their urinary leakage problem with their health care provider. Receiving urinary incontinence treatment: The percentage of patients 65 years of age and older who self-report having a urine leakage problem in the last six months and who received treatment for their current urine leakage problem.</td>
</tr>
<tr>
<td><strong>Numerator Statement:</strong> a) Discussing Urinary Incontinence: The number of patients who reported having a problem with urine leakage in the past 6 months and indicated they discussed their urine leakage problem with their current provider. b) Receiving Urinary Incontinence Treatment: The number of patients who reported having a problem with urine leakage in the past 6 months and indicated they received treatment for their current urine leakage problem.</td>
</tr>
<tr>
<td><strong>Denominator Statement:</strong> The number of patients 65 years and older who responded to the survey indicating they had accidentally leaked urine in the past 6 months and their urine leakage was a problem.</td>
</tr>
<tr>
<td><strong>Exclusions:</strong> N/A</td>
</tr>
<tr>
<td><strong>Adjustment/Stratification:</strong> No risk adjustment or risk stratification</td>
</tr>
<tr>
<td><strong>Level of Analysis:</strong> Health Plan, Integrated Delivery System</td>
</tr>
<tr>
<td><strong>Type of Measure:</strong> Process</td>
</tr>
<tr>
<td><strong>Data Source:</strong> Patient Reported Data/Survey</td>
</tr>
<tr>
<td><strong>Measure Steward:</strong> National Committee for Quality Assurance</td>
</tr>
</tbody>
</table>

MEMBER COMMENTS (August 7-21, 2012)
None

STEERING COMMITTEE MEETING (August 27-28, 2012)
### 0030 Urinary Incontinence Management in Older Adults - a. Discussing urinary incontinence, b. Receiving urinary incontinence treatment – A patient reported measure

<table>
<thead>
<tr>
<th>Importance to Measure and Report:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1a. High Impact:</strong> H-14; M-0; L-0; I-0</td>
</tr>
<tr>
<td><strong>Discussion:</strong> General agreement that incontinence addresses a high impact area. This is a bothersome issue that occurs in a high percentage of women.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evidence:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1c.</strong> Yes, body of evidence meets guidance for quantity, quality, consistency</td>
</tr>
<tr>
<td><strong>Discussion:</strong></td>
</tr>
<tr>
<td>• The developer’s review of the evidence did not specify how many RCTs were completed in the review of quantity of evidence.</td>
</tr>
<tr>
<td>• There was agreement among the GU experts that the evidence to support the guidelines (ACOG, SIGN) was sufficient to support this measure focus.</td>
</tr>
<tr>
<td><strong>0:</strong> No, body of evidence does not meet guidance for quantity, quality, consistency</td>
</tr>
<tr>
<td><strong>0:</strong> No, inadequate information to rate quantity, quality, consistency of body of evidence</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Performance Gap:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1b.</strong> H-13; M-2; L-0; I-0</td>
</tr>
<tr>
<td><strong>Discussion:</strong> Based on the data provided for this maintenance measure, the Committee agrees there is still a performance gap and an opportunity for improvement.</td>
</tr>
</tbody>
</table>

#### Recommendations to Developer for Stage 2:

- Consider adjusting the numerator to also include patients who were offered treatment, but refused. Currently, the numerator specifies that the patient had to receive treatment. Because treatment is a patient choice, not receiving treatment may not actually represent poor quality.
  - **Developer Response:** NCQA is working on a modified version of this measure. In about a year when testing is completed, this concern will be addressed in the updated measure. Because this measure is based on an established survey with specific questions, it is not easy to change.
- Update submission form to clarify the number (quantity) of studies, particularly RCT’s that support the measure focus.
- Expand age group to include commercial and menopausal population.

Steering Committee Recommendation for Approval of Concept: **Y-15; N-0**

**MEMBER & PUBLIC COMMENT (September 26 – October 25, 2012)**
0030 Urinary Incontinence Management in Older Adults - a. Discussing urinary incontinence, b. Receiving urinary incontinence treatment – A patient reported measure

**Member & Public Comment:**
- Two comments supporting this measure and agreeing with the steering committee that the numerator should include patients who are offered treatment and refuse. Refusing treatment is a valid care option selected by patients and, with proper patient engagement, does not necessarily indicate poor care. However, for this exclusion to apply, the measure developers must find a way to demonstrate that the patients were properly informed and actively engaged in their care decision.

**Committee response:**
- The Committee agrees that capturing the patient’s experience is an important aspect of measurement in counseling measures and considers these measures to be good start towards evaluating shared decision making because it reinforces the physician’s responsibility to discuss treatment options. Measure 0030 already captures the patient experience via the survey tool; however, the quality of this discussion and how it impacts the patient’s response may be best captured in a patient-reported outcome measure.

**CSAC REVIEW (November 7-8, 2012)**

**Decision:** Approved with the amendment that the Steering Committee recommendations must be addressed prior to stage two submission.

**BOD REVIEW (November 29 – December 11, 2012)**

**Decision:** Ratification of the CSAC decision on concept approval.
### Measure Concept Submission Form

**Status:** Maintenance, Original Endorsement: May 1, 2007  
**Description:** This is a clinical performance measure which assesses whether women age 65+ were provided appropriate treatment for urinary incontinence (UI). This measure has three rates:

(A) **Assessment for UI:** Percentage of female patients aged 65 years and older who were assessed for the presence or absence of urinary incontinence within 12 months.  
(B) **Characterization of UI:** Percentage of female patients aged 65 years and older with a diagnosis of urinary incontinence whose urinary incontinence was characterized at least once within 12 months.  
(C) **Plan of Care for UI:** Percentage of female patients aged 65 years and older with a diagnosis of urinary incontinence with a documented plan of care for urinary incontinence at least once within 12 months.

**Numerator Statement:** This measure has three rates. The numerator for each of the rates is as follows:

(A) **Assessment for UI:** Patients who were assessed for the presence or absence of urinary incontinence within 12 months.

(B) **Characterization of UI:** Patients whose urinary incontinence was characterized at least once within 12 months.

(C) **Plan of Care for UI:** Patients with a documented plan of care for urinary incontinence at least once within 12 months.

Urinary incontinence is defined as any involuntary leakage of urine. Characterization of urinary incontinence may include one or more the following: frequency, volume, timing, type of symptoms, and/or how bothersome to the patient. Plan of care may include behavioral interventions (e.g., bladder training, pelvic floor muscle training, prompted voiding), referral to specialist, surgical treatment, reassess at follow-up visit, lifestyle interventions, addressing co-morbid factors, modification or discontinuation of medications contributing to urinary incontinence, or pharmacologic therapy.

**Denominator Statement:** There are two denominators for the rates in this measure.

(A) **Assessment of UI:** All female patients aged 65 years and older who visited and eligible provider in the measurement year.

(B & C) **Characterization and Plan of Care for UI:** All female patients aged 65 years and older with a diagnosis of urinary incontinence who visited an eligible provider in the measurement year.

**Exclusions:** Documentation of medical reason(s) for not assessing the presence or absence of urinary incontinence within 12 months.

**Adjustment/Stratification:** No risk adjustment or risk stratification.

**Level of Analysis:** Clinician Group/Practice, Individual Clinician/Team.

**Type of Measure:** Process.

**Data Source:** Administrative claims.

**Measure Steward:** National Committee for Quality Assurance.

### MEMBER COMMENTS (August 7-21, 2012)

None

### STEERING COMMITTEE MEETING (August 27-28, 2012)

---

**NATIONAL QUALITY FORUM**
1. Importance to Measure and Report:

1a. High Impact: H-15; M-0; L-0; I-0
   
   **Discussion:** Similar impact as discussed in #0030. General agreement that incontinence is a high impact area.

1c. Evidence
   
   **13:** Yes, body of evidence meets guidance for quantity, quality, consistency
   
   **Discussion:** The Committee agreed that this measure was similar to NQF #0030; however, this measure is based on administrative claims and provides a different perspective than NQF #0030, which is based on patient report. The Committee was concerned that the evidence presented by the developer indicated that incontinence should be treated but did not provide evidence that documentation in the medical record improved incontinence. Some expressed concern about the link between this process measure and patient outcomes. However, the Committee ultimately agreed this measure meets the evidence criteria since existing literature does link discussion with the provider about urinary incontinence to improved outcomes.

   **0:** No, body of evidence does not meet guidance for quantity, quality, consistency

   **2:** No, inadequate information to rate quantity, quality, consistency of body of evidence

1b. Performance Gap: H-7; M-8; L-0; I-0
   
   **Discussion:**
   
   • While PQRS data does not show a performance gap, the Committee agreed that there is overall low performance and low reporting based on the data submitted.

**Recommendations to Developer for Stage 2:**

• eMeasure specifications are strongly recommended.
• Consider the addition of an option for patient choice of no treatment.
• Expand age group to include commercial and menopausal population.

**Steering Committee Recommendation for Approval of Concept:** Y-14; N-1

**MEMBER & PUBLIC COMMENT (September 26 – October 25, 2012)**
## 0098 Urinary Incontinence: Assessment, Characterization, and Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older – an administrative measure

### Member & Public Comments:
- Commenters were concerned that this measure was not closely linked to an outcome and would not be meaningful to all stakeholders.
- Suggestions were also made to pair the measure with an outcome measure or create a composite measure that accounts for urinary continence assessment, characterization, and plan of care.
- Commenters also desired a more inclusive age range.

### Committee response:
- The Committee agrees that measures closely linked to an outcome will provide the most meaningful information to stakeholders. Additionally, the Committee recommended that the measure age range be expanded to include the commercial and menopausal population.

### CSAC REVIEW (November 7-8, 2012)

**Decision:** Approved with the amendment that the Steering Committee recommendations must be addressed prior to stage two submission.

### BOD REVIEW (November 29 – December 11, 2012)

**Decision:** Ratification of the CSAC decision on concept approval.

## C 2038 Performing vaginal apical suspension (uterosacral, iliococygeus, sacrospinous or sacral colpopexy) at the time of hysterectomy to address uterovaginal prolapse

### Measure Concept Submission Form

**Description:** Percentage of female patients undergoing hysterectomy for the indication of uterovaginal prolapse in which a concomitant vaginal apical suspension (i.e. uterosacral, iliococygeus, sacrospinous or sacral colpopexy) is performed.

**Numerator Statement:** The number of female patients who have a concomitant vaginal apical suspension (i.e. uterosacral, iliococygeus, sacrospinous or sacral colpopexy) at the time of hysterectomy for uterovaginal prolapse.

**Denominator Statement:** Hysterectomy, performed for the indication of uterovaginal prolapse.

**Exclusions:**
- Patients with a gynecologic or other pelvic malignancy noted at the time of hysterectomy
- Patients undergoing a concurrent obliterative procedure (vaginectomy)
- Patients undergoing excision of prolapsed cervix only (prior sub-total hysterectomy)

**Adjustment/Stratification:** No, we do not plan to risk adjust the measure. No, we do not plan to stratify the measure results.

**Level of Analysis:** Clinician Group/Practice, Individual Clinician

**Type of Measure:** Process

**Data Source:** Administrative claims, Paper Medical Records

**Measure Steward:** American Urogynecologic Society

### MEMBER COMMENT (August 7-21, 2012)

None

### STEERING COMMITTEE MEETING (August 27-28, 2012)
Performing vaginal apical suspension (uterosacral, iliococygeus, sacrospinous or sacral colpopexy) at the time of hysterectomy to address uterovaginal prolapse

1. Importance to Measure and Report:

1a. High Impact: H-13; M-1; L-0; I-0
   Discussion: There was general agreement this measure focus is high impact as prolapse repair is a common procedure performed 100,000 to 200,000 per year. In addition to impacting a large number of individuals, the cost of treatment and rate of complications are high.

1c. Evidence

   14: Yes, body of evidence meets guidance for quantity, quality, consistency
   Discussion: The Committee agreed that there is good evidence supporting the measure focus in terms of published systematic reviews, including randomized controlled trials. The Committee also agreed that there is a clear link between this process and outcomes that are important to patients.

   0: No, body of evidence does not meet guidance for quantity, quality, consistency
   0: No, inadequate information to rate quantity, quality, consistency of body of evidence

1b. Performance Gap: H-12; M-1; L-0; I-1
   Discussion: Based on the data provided for this concept, the Committee agrees there is a performance gap and an opportunity for improvement.

Recommendations to Developer for Stage 2: None

Steering Committee Recommendation for Approval of Concept: Y-14; N-0

Member & Public Comment (September 26 – October 25, 2012)

Member & Public Comments:
- Comments in support of the measure as a significant tool for reducing the potential for repeat surgery
- Commenters were concerned that the measure does not address the fact that hysterectomies should only be performed with appropriate indications.

Committee response:
- While the Committee agrees that hysterectomies should only be performed for the appropriate indications, the focus of this measure is not on appropriate indication for hysterectomy for uterovaginal prolapse, but rather whether apical suspension was performed for those that did receive a hysterectomy. The Committee recommends that future measure development should focus on appropriate indication for hysterectomy for patients with uterovaginal prolapse.

CSAC REVIEW (November 7-8, 2012)

Decision: Approved with the amendment that the Steering Committee recommendations must be addressed prior to stage two submission.

BOD REVIEW (November 29 – December 11, 2012)

Decision: Ratification of the CSAC decision on concept approval.
C 2052 Reduction of Complications through the use of Cystoscopy during Surgery for Stress Urinary Incontinence (SUI)

Measure Concept Submission Form

Status: New Submission

Description: Percentage of SUI surgeries for which cystoscopy was used during the surgical procedure to reduce complications

Numerator Statement: Female patients who had SUI surgery for which cystoscopy was used during the surgical procedure to reduce complications

Denominator Statement: Female patients who had SUI surgeries (without concomitant surgery for prolapse)

Exclusions: Documentation of medical reason(s) for not using cystoscopy during SUI surgery (patients for whom the use of a cystoscope may not be appropriate, such as the presence of a new cystostomy repair). The panel noted that endoscopy after a new repair should be cautiously used. Concomitant prolapse surgery is an exclusion.

Adjustment/Stratification:

Level of Analysis: Individual Clinician

Type of Measure: Process

Data Source: Administrative claims, Paper Medical Records

Measure Steward: American Urological Association

MEMBER COMMENTS (August 7-21, 2012)

America's Health Insurance Plans - We recommend revising the measure name to more accurately reflect measurement of the number of women who have had complications through the use of cystoscopy during surgery for Stress Urinary Incontinence. Also, it will be difficult to identify appropriate denominator exclusions through administrative data and will require burdensome chart abstraction.

STEERING COMMITTEE MEETING (August 27-28, 2012)
C 2052 Reduction of Complications through the use of Cystoscopy during Surgery for Stress Urinary Incontinence (SUI)

1. Importance to Measure and Report:

1a. High Impact: H-13; M-2; L-0; I-0

Discussion: There is general agreement this measure focus addresses a high impact area. SUI surgery is a high volume procedure and cystoscopy is used to reduce complications.

1c. Evidence

5: Yes, body of evidence meets guidance for quantity, quality, consistency
9: No, body of evidence does not meet guidance for quantity, quality, consistency

Discussion:
- The evidence to support the three guidelines (European Urology, AUA, ACOG) submitted are all consensus based and no further systematic review of the evidence was performed or documented in the submission form.
- Due to the lack of information in the evidence portion of the submission form, the Committee focused their discussion on the information submitted in the performance gap section. The submission notes that cystoscopy has been shown to improve patient safety, but is not necessary. The submission subsequently notes the improved rates of identifying injuries during surgery with the use of cystoscopy are based on three observational studies. The Committee weighed this conflicting information, the controversy over cost effectiveness, the possible surgical techniques that can be used, the risk to the patient to perform the cystoscopy, and determined it is low risk (1% chance of bladder infection) and high benefit for the patient. The GU experts agreed that there is general consensus that this should be done; while the rate of injury may be low, the consequences of not identifying an injury are very high.
- Within their discussion, the Committee rated the evidence as low quality, moderate quantity, and consistency is high for use of cystoscopy.
- The evidence does not exist at all to support the measure focus. (i.e., no empirical evidence).
- There’s an exceptional and compelling reason that the measure should be considered further (i.e., benefits outweigh the harms): Y-13; N-2

1b. Performance Gap: H-2; M-7; L-4; I-2

Discussion: While the information for the gap was inconsistently presented there was general agreement based on the Committee’s expert opinion there is a moderate gap.

Recommendations to Developer for Stage 2:
- Exclusions: concomitant surgery should not be excluded.
- Gap information needs to be improved.
- Measure should be stratified by procedure.
- Feasibility and usability of this measure may be impacted by the inability to capture all the cystoscopies with available codes.
- Combine with C 2063 Use of cystoscopy concurrent with prolapse repair surgery (This recommendation changed following member comment period).
### C 2052 Reduction of Complications through the use of Cystoscopy during Surgery for Stress Urinary Incontinence (SUI)

**Steering Committee Recommendation for Approval of Concept:** Y-11; N-4

**MEMBER & PUBLIC COMMENT (September 26 – October 25, 2012)**

**Member & Public Comments:**

- Comments supporting the concept focus as way to improve quality of care and reduce the cost of reparative health care. A sling injury identified at the time of surgery will reduce long-term complications.

- Commenters cautioned against combining concept C2052 with C2063: *Use of Cystoscopy Concurrent with Prolapse Repair Surgery* because it would limit the usefulness of measuring two distinct populations. Vaginal prolapse and urinary incontinence, although sometimes found together are separate and distinct conditions. Although surgical correction of these conditions can be concurrent, surgery for prolapse is often performed separately from surgery for urinary incontinence. Similarly, cystoscopy performed at the time of sling is done to evaluate for bladder and urethral injuries whereas cystoscopy after prolapse surgery includes evaluation for ureteral integrity.

**Committee response:**

- The Committee discussed several considerations both for combining the measures and keeping them as separate measures. GU experts on the Committee acknowledged that while the risk for complications between these two populations of patients is similar, the cystoscopy for the two procedures is used to identify different potential complications. Ultimately, the Committee agreed with commenters that the concepts should be approved and reviewed in stage two as separate measures. Once these concepts are fully specified and tested, endorsed, implemented and reported separately, a decision can be made at the time of maintenance as to whether further harmonization or combining of these measures is necessary. Further, some Committee experts agree that patients who have both procedures performed at the same time should be counted in each measure.

**CSAC REVIEW (November 7-8, 2012)**

**Decision:** Approved with the amendment that the Steering Committee recommendations must be addressed prior to stage two submission.

**BOD DECISION (November 29 – December 11, 2012)**

**Decision:** Ratification of the CSAC decision on concept approval.
**C 2063 Use of cystoscopy concurrent with prolapse repair surgery**

**Measure Concept Submission Form**

**Status:** New Submission

**Description:** Percentage of patients that undergo concurrent cystoscopy at the time of surgery for correction of anterior and/or apical vaginal prolapse to check for lower urinary tract injury.

**Numerator Statement:** Numerator is the number of female patients where a concurrent intraoperative cystoscopy was performed at the time of surgery for correction of anterior and/or apical vaginal prolapse to check for lower urinary tract injury.

**Denominator Statement:** Denominator is the number of female patients undergoing any prolapse repair surgery for correction of anterior and/or apical vaginal prolapse.

**Exclusions:** There are no exclusions from the target population.

**Adjustment/Stratification:** We are not planning to risk adjust this measure. We do not plan to stratify the results.

**Level of Analysis:** Clinician Group/Practice, Individual Clinician

**Type of Measure:** Process

**Data Source:** Administrative claims, Paper Medical Records

**Measure Steward:** American Urogynecologic Society

**MEMBER COMMENTS (August 7-21, 2012)**

America’s Health Insurance Plans - We are concerned that this measure does not meet the importance criterion as it does not focus on a demonstrated high-impact aspect of healthcare. Also, this measure is not easily collected through administrative data and will require burdensome chart abstraction. We recommend combining this measure with #C 2038 into a single prolapse surgery measure.

**STEERING COMMITTEE MEETING (August 27-28, 2012)**

1. Importance to Measure and Report:

1a. High Impact: H-8; M-6; L-0; I-0

**Discussion:** There is general agreement this measure focus addresses a high impact area.

1c. Evidence

12: Yes, body of evidence meets guidance for quantity, quality, consistency

**Discussion:** There is a moderate amount of evidence on the use of cystoscopy used specifically in prolapse surgery; however, if evidence related to hysterectomy is included the body of evidence is broader to support the measure focus. These procedures are similar enough that the evidence can be considered applicable to both procedures. The Committee agreed the concept meets the evidence criteria.

2: No, body of evidence does not meet guidance for quantity, quality, consistency

0: No, inadequate information to rate quantity, quality, consistency of body of evidence

1b. Performance Gap: H-1; M-10; L-3; I-0

**Discussion:** Based on the data provided for this concept, the Committee agrees there is a performance gap and an opportunity for improvement.
C 2063 Use of cystoscopy concurrent with prolapse repair surgery

**Recommendations to Developer for Stage 2:**
- Consider how data will be collected to implement this measure. The use of CPT codes to identify cystoscopy (that is bundled with anterior repair) may be an issue for validity and reliability testing in stage 2.
- Combine with C 2052 Reduction of Complications through the use of Cystoscopy during Surgery for Stress Urinary Incontinence (SUI) (This recommendation changed following member comment period).

**Steering Committee Recommendation for Approval of Concept: Y-14; N-0**

### Member & Public Comment (September 26 – October 25, 2012)

- Commenters cautioned against combining concept C2063 with C2052: Reduction of Complications through the use of Cystoscopy during Surgery for Stress Urinary Incontinence (SUI) because it would limit the usefulness of measuring two distinct populations. Vaginal prolapse and urinary incontinence, although sometimes found together are separate and distinct conditions. Although surgical correction of these conditions can be concurrent, surgery for prolapse is often performed separately from surgery for urinary incontinence. Similarly, cystoscopy performed at the time of sling is done to evaluate for bladder and urethral injuries whereas cystoscopy after prolapse surgery includes evaluation for ureteral integrity.

### Committee response:
- The Committee discussed several considerations both for combining the measures and keeping them as separate measures. GU experts on the Committee acknowledged that while the risk for complications between these two populations of patients is similar, the cystoscopy for the two procedures is used to identify different potential complications. Ultimately the Committee agreed with commenters that the concepts should be approved and reviewed in stage two as separate measures. Once these concepts are fully specified and tested, endorsed, implemented and reported separately, a decision can be made at the time of maintenance as to whether further harmonization or combining of these measures is necessary. Further, some Committee experts agree that patients who have both procedures performed at the same time should be counted in each measure.

### CSAC REVIEW (November 7-8, 2012)

**Decision:** Approved with the amendment that the Steering Committee recommendations must be addressed prior to stage two submission.

### BOD REVIEW (November 29 – December 11, 2012)

**Decision:** Ratification of the CSAC decision on concept approval.
<table>
<thead>
<tr>
<th>Measure Concept Submission Form</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status:</strong> Maintenance, Original Endorsement: December 4, 2009</td>
</tr>
<tr>
<td><strong>Description:</strong> The percentage of adult patients with gastroesophageal reflux disease (GERD) with alarm symptoms who have had an upper gastrointestinal study.</td>
</tr>
<tr>
<td><strong>Numerator Statement:</strong> Patients who have had an upper gastrointestinal study</td>
</tr>
<tr>
<td><strong>Denominator Statement:</strong> Patients, 18 years and older, diagnosed with GERD with alarm symptoms (e.g., dysphagia, iron deficiency anemia, weight loss)</td>
</tr>
<tr>
<td><strong>Exclusions:</strong> Specific Exclusions:</td>
</tr>
<tr>
<td>1. Patients with a documented gastrointestinal malignancy</td>
</tr>
<tr>
<td>2. Patients with other causes of the alarm symptoms including esophageal varices, known Barrett's esophagus, or gastric restrictive procedures</td>
</tr>
<tr>
<td>General Exclusions:</td>
</tr>
<tr>
<td>Metastatic malignancy, chemotherapy/radiation therapy, hospice and Skilled Nursing Facility, feedback from physician indicating GI study contraindicated or not applicable.</td>
</tr>
<tr>
<td><strong>Adjustment/Stratification:</strong> No risk adjustment or risk stratification</td>
</tr>
<tr>
<td><strong>Level of Analysis:</strong> National, Regional</td>
</tr>
<tr>
<td><strong>Type of Measure:</strong> Process</td>
</tr>
<tr>
<td><strong>Data Source:</strong> Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Healthcare Provider Survey, Patient Reported Data/Survey, Electronic Clinical Data: Pharmacy</td>
</tr>
</tbody>
</table>

**Measure Steward:** ActiveHealth Management

**MEMBER COMMENTS (August 7-21, 2012)**

*America’s Health Insurance Plans* - This measure cannot be easily collected through administrative data and will require burdensome chart abstraction; however, it is a good registry measure. We are also concerned that as written, the “sensitivity” of the measure appears to be problematic (issues with identifying appropriate use) and could therefore falsely suggest overuse.

**STEERING COMMITTEE MEETING (August 27-28, 2012)**
1. Importance to Measure and Report:

1a. High Impact: H-2; M-7; L-5; I-1

Discussion:
- The Committee discussed the seemingly small number of patients that would be captured in this measure given the measure focus. Based on the data provided, it appears to be a small population of people who actually have alarm symptoms that would be impacted by this measure; patients with GERD and with alarm symptoms are a very small population. Given the severity and implications for treatment of the small population represented by the measure, this measure focus could be impactful. It is potentially a vulnerable population. The Committee also expressed some concerns about physician documentation and capturing dysphagia and weight loss with administrative claims data. It is very difficult to identify these patients.
- These questions around definitions and issues of validity and reliability will become important in stage 2.

1c. Evidence

4: Yes, body of evidence meets guidance for quantity, quality, consistency
1: No, body of evidence does not meet guidance for quantity, quality, consistency
10: No, inadequate information to rate quantity, quality, consistency of body of evidence

Discussion:
- The sensitivity of the practice to identify cancers in patients with alarm symptom is about 67%, which is equivalent to other cancer screening tests like PSA and mammography.
- There is general agreement that the quantity, quality, and consistency of the body of evidence meet the NQF guidance: Y-10; N-5

Discussion: The Committee agreed there is significantly more evidence available on this measure focus than was presented in the submission. While the Committee agreed the evidence submitted was insufficient, there was agreement that they would exercise the evidence exception to continue to review the concept, since the quality, quantity, and consistency of the evidence would support this measure focus if provided.

1b. Performance Gap: H-0; M-2; L-13; I-0

Discussion:
- Overutilization of esophagogastroduodenoscopy (EGD) is very common so there was some concern on whether there is actually underutilization for this population.
- From the specialist standpoint there is likely not a major performance gap, but for Primary Care Providers (PCP) there may be a larger performance gap.
- This maintenance measure is currently tested only at the population level and the Committee raised concerns on the usability of this measure at that level. This will be discussed in Stage 2.
**0622 GERD - Upper Gastrointestinal Study in Adults with Alarm Symptoms**

**Recommendations to Developer for Stage 2:**
- This measure should include chronic GERD patients.
- The exclusion should be clarified as previous malignancy.
- Barrett’s esophagus should be included.
- The measure should be expanded to include patients under 18 as well; pediatric populations should be included as the same evidence applies.
- Additional evidence should be provided for evidence criterion.
- Additional information on performance gap is needed.
- Define/specify the testing/procedures for the numerator more clearly.
- Consider specifying the numerator in a patient population in which it would have more broadly impact (e.g., obese and/or male patients)

**Steering Committee Recommendation for Approval of Concept: Y-14; N-1**

**Discussion:** The concept has been recommended for approval, but will be considered for reserve status in Stage 2 since there was a limited performance gap.

**MEMBER & PUBLIC COMMENT (September 26 – October 25, 2012)**

**Member & Public Comments:**
- Commenters were concerned that measure is not closely link to outcomes and that it is an example of a “check the box” measure.

**Committee response:**
- Given the severity and implications for treatment, the Committee agreed that this is an important process measure for this population.

**CSAC REVIEW (November 7-8, 2012)**

Approved with the amendment that the Steering Committee recommendations must be addressed prior to stage two submission.

**BOD REVIEW (November 29 – December 11, 2012)**

**Decision:** Ratification of the CSAC decision on concept approval.
Measure Concept Submission Form

Status: Maintenance, Original Endorsement: December 4, 2009

Description: The percentage of adult patients with chronic liver disease who have received a hepatitis A vaccine

Numerator Statement: Patients with chronic liver disease who have received a hepatitis A vaccine or who have been tested for immunity in the past. Keeping in consideration that providers who test for Hepatitis A immunity most likely intend to take action on the test results and that hepatitis A testing is usually communicated in the form of LOINC codes which do not indicate immunity confirmed, immunity testing is considered sufficient for completion of the numerator for this measure.

Denominator Statement: All patients, ages 18 and older, diagnosed with chronic liver disease

Exclusions: Patients with a previous history of viral hepatitis A. General exclusions: 1. Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months; 2. Patients who have been in a skilled nursing facility in the last 3 months (this exclusion is included to avoid holding physicians who care for patients during a transitional period, e.g. temporary SNF placement, for their ongoing care; hence, the time limitation of 3 months).

Adjustment/Stratification: No risk adjustment or risk stratification

Level of Analysis: Population: National, Population: Regional

Type of Measure: Process

Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Healthcare Provider Survey, Electronic Clinical Data: Laboratory, Patient Reported Data/Survey, Electronic Clinical Data: Pharmacy

Measure Steward: ActiveHealth Management

MEMBER COMMENTS (August 7-21, 2012)

America’s Health Insurance Plans - While this measure can be calculated using administrative data, there may be challenges with assessing the numerator at the health plan level in instances where patients have received the vaccination but who have also changed health plans.
## Importance to Measure and Report:

### 1a. High Impact: H-7; M-8; L-0; I-0

**Discussion:** The developer cited literature that shows that chronic liver disease is quite prevalent and common, and the patients with chronic liver disease who develop hepatitis A often have higher rates of fulminant hepatitis and mortality.

### 1c. Evidence

13: Yes, body of evidence meets guidance for quantity, quality, consistency  
1: No, body of evidence does not meet guidance for quantity, quality, consistency  
1: No, inadequate information to rate quantity, quality, consistency of body of evidence  

**Discussion:** The Committee agreed that the three guidelines cited by the developer were based on a moderate quality, quantity and high consistency level of evidence. The evidence was derived from observational studies, time series studies and expert opinion supporting the guidelines.

### 1b. Performance Gap: H-11; M-3; L-1; I-0

**Discussion:** Based on the data provided for this maintenance measure from the ActiveHealth database there is a 64% performance gap. The Committee agrees this is a significant performance gap and an opportunity for improvement.

### Recommendations to Developer for Stage 2:

- The numerator is inconsistent with title of measure; consider changing the title of the measure to more closely align with the measure focus.
- Based on the data provided for this maintenance measure from the ActiveHealth database there is a 64% performance gap. The Committee agrees this is a significant performance gap and an opportunity for improvement.
- Understanding there are differences in data sources, harmonize with #0399 under review in the NQF Infectious Disease project
  - **Developer Response:** Developers acknowledged and agreed

### Steering Committee Recommendation for Approval of Concept: Y-15; N-0

### Member & Public Comment (September 26 – October 25, 2012)

- No comments received

### CSAC REVIEW (November 7-8, 2012)

**Decision:** Approved with the amendment that the Steering Committee recommendations must be addressed prior to stage two submission.

### BOD REVIEW (November 29 – December 11, 2012)

**Decision:** Ratification of the CSAC decision on concept approval.
**0658 Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients**

**Measure Concept Submission Form**

**Status:** Maintenance, Original Endorsement: January 17, 2011 (Time-limited)

**Description:** Percentage of patients aged 50 years and older receiving a screening colonoscopy without biopsy or polypectomy who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report.

**Numerator Statement:** Patients who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report

**Denominator Statement:** All patients aged 50 years and older receiving screening colonoscopy without biopsy or polypectomy

**Exclusions:** Documentation of medical reason(s) for not recommending at least a 10 year follow-up interval (eg, above average risk patient, inadequate prep)

**Adjustment/Stratification:** No risk adjustment or risk stratification

**Level of Analysis:** Clinician Group/Practice, Individual, Clinician/Team

**Type of Measure:** Process

**Data Source:** Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Electronic Clinical Data: Imaging/Diagnostic Study, Electronic Clinical Data: Registry

**Measure Steward:** American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)

**MEMBER COMMENTS (August 7-21, 2012)**

None

**STEERING COMMITTEE MEETING (August 27-28, 2012)**

1. **Importance to Measure and Report:**

1a. High Impact: H-15; M-0; L-0; I-0

   **Discussion:** There is general agreement this concept meets the high impact criterion.

1c. **Evidence**

   15: Yes, body of evidence meets guidance for quantity, quality, consistency

   **Discussion:**
   - There is a significant amount of evidence to support this measure focus.
   - There was discussion on whether the 10 year interval specified in this concept is based on evidence or consensus. Most polyps > 1 cm in diameter appear to grow for 5-10 years before becoming colorectal cancer. Usefulness of an interval beyond 10 years has not been studied. Committee members noted that prospective studies have demonstrated that very few patients (< 3%) have advanced adenomas when colonoscopy is repeated 5 years after a normal screening colonoscopy. Evidence in the submission form was not graded, but it is supported in the guidelines.

0: No, body of evidence does not meet guidance for quantity, quality, consistency

0: No, inadequate information to rate quantity, quality, consistency of body of evidence

1b. **Performance Gap:** H-15; M-0; L-0; I-0

   **Discussion:** Based on the data provided for this maintenance measure, the Committee agrees there is still a performance gap and an opportunity for improvement.
### 0658 Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients

#### Recommendations to Developer for Stage 2:
- Rather than measuring whether the appropriate interval was recommended, consider specifying the measure, for example, patients aged 60 years or older receiving a screening colonoscopy who are documented to have had their last screening colonoscopy 10 or more years prior. Implementing these changes would make the measure closer to an outcome measure that would be more impactful. The Committee recognized that to implement a prospective outcome measure is difficult based on availability of data.
- Patients aged 50 years and older receiving a screening colonoscopy who had a recommendation to repeat colonoscopy in 1 year or less due to poor bowel cleansing
- Consider adjusting the upper age limit for older patients, including inflammatory bowel disease, and better define "above average risk".
- Clarify in the specifications whether the exceptions are included in the denominator or should be calculated as a separate measure.
- Due to the differences in populations and the measure focus, harmonization between this concept and 0659 will not be needed.

#### Steering Committee Recommendation for Approval of Concept: Y-15; N-0

#### MEMBER & PUBLIC COMMENT (September 26 – October 25, 2012)

**Member & Public Comments:**
- Commenters were concerned that the measure exclusions provide loopholes for providers to manipulate the measure results.
- The lack of information about previous colonoscopies may hide evidence of poor care.
- Pairing this measure with an appropriate outcome measure would make it more meaningful to all stakeholders.

**Committee response:**
- The Committee agreed that manipulation of results through gaming is a concern; however, the specific medical reason for the exclusion must be documented through the use of CPT-II codes. The Committee recommended that the specifications for the exclusions include a specific list of the types of medical reasons that are acceptable for this exclusion when the measures are submitted for the Stage 2 measure evaluation.

#### CSAC REVIEW (November 7-8, 2012)

**Decision:** Approved with the amendment that the Steering Committee recommendations must be addressed prior to stage two submission.

#### BOD REVIEW (November 29 – December 11, 2012)

**Decision:** Ratification of the CSAC decision on concept approval.
# 0659 Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use

**Measure Concept Submission Form**

**Status:** Maintenance, Original Endorsement: Jan 17, 2011 (Time-limited)

**Description:** Percentage of patients aged 18 years and older receiving a surveillance colonoscopy, with a history of a prior colonic polyp in previous colonoscopy findings who had a follow-up interval of 3 or more years since their last colonoscopy documented in the colonoscopy report

**Numerator Statement:** Patients who had an interval of 3 or more years since their last colonoscopy

**Denominator Statement:** All patients aged 18 years and older receiving a surveillance colonoscopy with a history of a prior colonic polyp in a previous colonoscopy

**Exclusions:** Documentations of medical reason(s) for an interval of less than 3 years since the last colonoscopy (eg, last colonoscopy incomplete, last colonoscopy had inadequate prep, piecemeal removal of adenomas, or last colonoscopy found greater than 10 adenomas)

OR

Documentation of a system reason(s) for an interval of less than 3 years since the last colonoscopy (eg, unable to locate previous colonoscopy report, previous colonoscopy report was incomplete)

**Adjustment/Stratification:** No risk adjustment or risk stratification. We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected. Stratification by insurance coverage (Commercial, Medicare and Medicaid) is recommended by some implementers.

**Level of Analysis:** Clinician Group/Practice, Individual, Clinician/Team

**Type of Measure:** Process

**Data Source:** Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Imaging/Diagnostic Study, Electronic Clinical Data : Registry

**Measure Steward:** American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)

**MEMBER COMMENTS (August 7-21, 2012)**

None

**STEERING COMMITTEE MEETING (August 27-28, 2012)**
0659 Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use

1. Importance to Measure and Report:

1a. High Impact: **H-15; M-0; L-0; I-0**

Discussion: There is general agreement this measure focus addresses a high impact area as it is one of the most overused procedures.

1c. Evidence

14: Yes, body of evidence meets guidance for quantity, quality, consistency

Discussion:
- The Committee discussed the length of screening intervals and the yield of identifying adenomas.
- The Committee reviewed evidence cited in the guidelines that was not specifically provided by the measure developer. Based on this review, the Committee determined that there is high quality of evidence demonstrating that these are appropriate intervals, and that the expected benefits are consistent.
- The interval specified in the measure does not match the recommendations in the evidence 3+ years versus 5 years

0: No, body of evidence does not meet guidance for quantity, quality, consistency

1: No, inadequate information to rate quantity, quality, consistency of body of evidence

1b. Performance Gap: **H-4; M-10; L-0; I-1**

Discussion:
- While the PQRS data does not suggest a performance gap, few physicians reported on this measure. However, the Committee did not believe that the submitted data is representative of the likely performance gap. The use of EHRs for this measure could demonstrate a larger performance gap. PQRS also only takes patients 65 years and older, so it is not capturing patients in the commercial population.

Recommendations to Developer for Stage 2:
- The developer should expand on the available evidence and on the details of the meta-analysis to better demonstrate the body of evidence available to support this measure focus.
- eMeasure specifications should be submitted in stage 2.
- The interval specified in the measure does not match the recommendations in the evidence 3+ years versus 5 years; consider how these can be aligned to ensure the measure is evidence-based.
- Due to the differences in populations and the measure focus, harmonization between this concept and 0658 will not be needed.

Steering Committee Recommendation for Approval of Concept: **Y-15; N-0**

**MEMBER & PUBLIC COMMENT (September 26 – October 25, 2012)**
### Member & Public Comments:
- Commenters were concerned that the measure exclusions provide loopholes for providers to manipulate the measure results.
- The lack of information about previous colonoscopies may hide evidence of poor care.
- Pairing this measure with an appropriate outcome measure would make it more meaningful to all stakeholders.

### Committee response:
- The Committee agreed that manipulation of results through gaming is a concern; however, the specific medical reason for the exclusion must be documented through the use of CPT-II codes. The Committee recommended that the specifications for the exclusions include a specific list of the types of medical reasons that are acceptable for this exclusion when the measures are submitted for the Stage 2 measure evaluation.

### CSAC REVIEW (November 7-8, 2012)

**Decision:** Approved with the amendment that the Steering Committee recommendations must be addressed prior to stage two submission.

### BOD REVIEW (November 29 – December 11, 2012)

**Decision:** Ratification of the CSAC decision on concept approval.
C 2056 Colonoscopy Quality Index

**Measure Concept Submission Form**

**Status:** New Submission

**Description:** This is a composite measure of the percentage of patients undergoing screening or surveillance colonoscopy who meet all individual quality elements (Appropriate indication for colonoscopy, standardized assessments of medical risk and bowel preparation, complete examination with photo documentation, free of serious complications, withdrawal time recorded, all essential polyp information recorded if polyp(s) identified, recommendation for follow-up colonoscopy consistent with patient history and examination findings), and the completion rate of each individual quality element.


**Denominator Statement:** All adults undergoing screening or surveillance colonoscopy

**Exclusions:** Patients with a personal or family history of familial adenomatous polyposis, hereditary non-polyposis colorectal cancer or inflammatory bowel disease are excluded from the denominator. Patients assessed as poor or unsatisfactory bowel preparation are excluded from the denominator.

**Adjustment/Stratification:** N/A - Procedural quality bundled measure. Although there is no data to support or refute, the quality of the colonoscopy procedure should not vary by case mix/risk as patients with a personal or family history of familial adenomatous polyposis, hereditary non-polyposis colorectal cancer or inflammatory bowel disease or patients assessed as poor or unsatisfactory bowel preparation are excluded from the denominator. These situations are excluded because of the need for highly individualized recommendations given the particular patient history and current clinical situation. This measure is not risk adjusted because it is a subgroup of low-risk patients; it does not make sense to risk adjust when there is minimal variation in risk for the population considered (e.g., all varying degrees of low risk). None

**Level of Analysis:** Facility, Clinician : Group/Practice, Clinician : Individual, Population : Regional

**Type of Measure:** Process

**Data Source:** Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Laboratory, Other, Paper Medical Records, Electronic Clinical Data : Registry

**Measure Steward:** Quality Quest for Health of Illinois, Inc.

**MEMBER COMMENT (August 7-21, 2012)**

*American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy – See Letter*

**STEERING COMMITTEE MEETING (August 27-28, 2012)**

1. **Importance to Measure and Report:**

1a. **High Impact:** H-15; M-0; L-0; I-0

**Discussion:**

- The focus for impact is on the broad area of colonoscopy screening surveillance.
- Colon cancer is the 2nd leading cause of cancer in the U.S.
- From a consumer perspective, the Committee agreed that composites are important and easily understood. There was general agreement that this measure focus addresses a high impact area.
C 2056 Colonoscopy Quality Index

1c. Evidence

0: 1=Yes, body of evidence meets guidance for quantity, quality, consistency
12: 2=No, body of evidence does not meet guidance for quantity, quality, consistency

Discussion by component:

• 1. Appropriate Indication for Colonoscopy: The Committee agreed that good medical practice should include the indication and thus is not needed as a national consensus standard for quality measurement. The Committee agreed that the evidence submitted is based only on consensus opinion.

• 2. Standardized Medical Risk Assessment: The Committee reiterated that this is standard clinical practice with evidence that is based only on consensus opinion. Further, as part of a standardized medical risk assessment, a cardiac risk assessment is done. However, documentation of this process as a quality indicator reported by the endoscopist could be problematic as it is frequently completed by the anesthesiologist and the endoscopist and would be difficult to operationalize consistently at a national level.

• 3. Standardized assessment of bowel prep: The Committee agreed that this is an important component. Members discussed multiple registry/database studies that indicate the quality of the bowel prep results in improved adenoma detection rate; however, this evidence was not provided in the measure submission.

• 4 & 5 Complete Examination and Cecal Photo Taken: The Committee agreed that these are generally accepted as a standard of practice. These indicators demonstrate that the colonoscopy reached the cecum. The Committee agreed that there is strong evidence in terms of registry/database data and a RCT to support the notion that failure to reach the cecum is associated with a higher risk of having interval cancers but was not discussed on the submission form.

• 6 & 7 All essential polyp information recorded and withdrawal time recorded: The Committee agreed that there is evidence of endoscopic registry/database studies that demonstrate that if the withdrawal time is greater than 7 minutes, the adenoma detection rate is higher than if the withdrawal time is less than 7 minutes. Therefore, this information may be useful to record. However, Committee members noted that adenoma detection rate is the key quality indicator for colorectal cancer screening with colonoscopy since the purpose of this procedure is to identify and remove adenomas. These two indicators are not sufficiently related to the adenoma detection rate. There is evidence that endoscopists with withdrawal times of more than seven minutes still have poor adenoma detection rates. The Committee also discussed that those with withdrawal times longer than 10 minutes may also have lower detection rates. This evidence was not provided in the measure submission form. The Committee was also concerned that this component only requires that the withdrawal time is recorded which can be “gamed” by the endoscopist so this may not improve outcomes. Others were also concerned that essential information about the polyp is not included in this measure, including whether pathologic examination of the polyp revealed it to be an adenoma. Low adenoma detection rate (but not short withdrawal time) has been associated
with an increased risk of interval colorectal cancers.

- Across components 3-7: There is a focus on the endoscopist's ability to ensure that the entire colon has been examined and all polyps have been removed. The Committee discussed that these components ultimately try to assess whether the colonoscopy is going to minimize or prevent patients from getting colon cancer in the future. The Committee expressed concern that the evidence does not support the link of these processes to the outcome of interest, specifically the adenoma detection rate.

- 8. Free of Serious Complications: In order to identify serious complications, the provider would need to follow up with the patient within a 15 to 30 day time window. The Committee discussed that documenting complications during the time of colonoscopy or in the first 24 hours after colonoscopy as this measure is currently specified would not assess the true rate of complications. While there is no disagreement that any complications experienced during the procedure should also be reported, the most common serious complication, post-polypectomy bleeding, usually does not occur until 2-14 days after colonoscopy and would not be captured by this indicator. The Committee was concerned that inclusion of only patients free of serious complications at the time of colonoscopy or in the first 24 hours after colonoscopy would not be an accurate representation of all complications that could occur.

- 9. Appropriate follow-up recommendation: The Committee generally agreed that the desired outcome should be to determine whether a quality colonoscopy is done. Each of these process components should demonstrate how they improve outcomes, specifically the adenoma detection rate. The identification of an adenoma can be determined within 72 hours of the procedure.

The developer was asked to submit evidence for each of the nine composite components; however, the evidence submitted for most of the components was insufficient and repeated for each component. The Committee therefore voted on the evidence for all components of the composite in a single vote and agreed that the evidence submitted was insufficient.

- The evidence submitted does not exist to support the measure focus (i.e., no empirical evidence) for all components of the composite.

- There is an exceptional and compelling reason that the measure should be considered further (i.e., benefits outweigh the harms): Y-0; N-15

3: No, inadequate information to rate quantity, quality, consistency of body of evidence

1b. Performance Gap:

**Discussion:** There was no discussion of gap as the measure did not pass evidence.
Recommendations to Developer:

- Consider weighting for certain components of the composite based on severity of complications associated with that component.
- Future submissions should reference evidence that is specific to each of the components.
- Consider developing a composite that is a hybrid of process and outcome measures that includes component measures on the most important outcomes related to the colonoscopy.
- Consider a composite that includes components with the highest evidence and impact, including a standardized assessment of bowel prep and completeness of colonoscopy including cecal photo taken that would indicate a failure to reach the cecum. Withdrawal time and serious complications within 14 days of colonoscopy should also be included.
- Consider which process components might link closer to the desired outcome of increasing the adenoma detection rate.
- An adenoma detection rate would be important to include in future composites.

Steering Committee Recommendation for Approval of Concept:

Discussion:

- The purpose of the composite is to allow consumers and purchasers to determine whether the colonoscopist is doing a quality job.
- The desired outcome of a colonoscopy should be to detect cancer (i.e. adenoma detection) and there is concern that this measure does not focus on processes that significantly impact that outcome.
- This concept is not recommended for approval. The concept did not pass the evidence criterion.

MEMBER & PUBLIC COMMENT (September 26 – October 25, 2012)

Member & Public Comment included:

- Multiple commenters submitted comments in support of this concept.
- Due to the length and volume of comments submitted, specific comments can be found in the table of submitted comments.

CONCEPT RECONSIDERATION (October 31, 2012)

The developer requested that the Committee reconsider the concept in light of additional evidence provided to support the components of the composite. (Letter).

Committee Reconsideration:

The Committee re-evaluated the evidence for each component of the Colonoscopy Quality Index based on the information submitted by the developer subsequent to the Committee’s first evaluation of the concept. (*Composite elements recommended by the Committee)

1. *Appropriate Indication for Colonoscopy
   - This component is supported by multiple medical specialty society guidelines. There is substantial evidence to show there is variability in the adherence to these guidelines and would therefore be an appropriate part of a quality index.

2. Standardized Medical Risk Assessment
   - This component only requires that the colonoscopist documents the American Society of Anesthesiology (ASA) score. This component within the composite as defined does not provide the documented score. Ultimately, the Committee agreed this assessment is standard medical practice and does not represent whether or not an endoscopist has
performed a high-quality colonoscopy for colorectal cancer screening or colon polyp surveillance. Further, there is no evidence submitted by the developer or known by the Committee, which shows that performing a colonoscopy procedure on a patient with an ASA greater than three, for example, leads to poor outcomes.

3. Standardized Assessment of Bowel Prep
   - The Committee agreed that poor bowel preparation is associated with lower adenoma detection rates and that adequate bowel preparation is essential to performing a high quality colonoscopy. There is high quality and consistent evidence to support this. However, as specified this measure within the composite only requires that the colonoscopist documented that they assessed the quality of the bowel preparation. Similar to the previous component, this component has no bearing on whether the colonoscopy had to be rescheduled due to poor bowel preparation; the colonoscopist could get credit even if they documented that the patient had poor bowel preparation, which is not a signal of performing a quality colonoscopy.

4. *Complete Examination
   - There is sufficient evidence to support that failure to reach the cecum has been associated with a higher risk of interval cancers and that this is an essential component to performing a high quality colonoscopy (e.g., diagnosing a colon cancer in a patients within 5 years after a normal screening colonoscopy).

5. *Cecal Photo Taken
   - While the Committee agreed that photo-documentation of the ileocecal valve and appendiceal orifice is not perfect documentation that the cecum was reached as there is variability in the skills to capture the appropriate structures, it is the best measure at this point in time.

6. *All Essential Polyp Information Recorded
   - The Committee recognized that based on how the composite is structured to collect data for the other components, it is not possible to satisfy Item 9 if these data are not included in the endoscopy report. There was a recommendation to improve this component by including the pathology results regarding adenoma detection.

7. Withdrawal Time was Recorded
   - There is sufficient evidence that has shown that mean withdrawal time of > 6 minutes has been associated with higher adenoma detection rates compared to individuals with mean withdrawal time of < 6 minutes. In this component of the index, endoscopists are graded based upon whether or not they record and document their withdrawal time. Similar to components 2 & 3, documentation of the withdrawal time is not an indication of a quality colonoscopy as the colonoscopist could get credit for a withdrawal time that is outside of the timeframe shown to produce the highest adenoma detection rates. The Committee acknowledged that a key indicator for identifying quality colonoscopist is the adenoma detection rate, which cannot be applied to an individual colonoscopy and incorporated into a composite such as this. Further, the Committee believes withdrawal time is most helpful when assessed in combination with adenoma detection rates. For example, if an endoscopist has a mean withdrawal time < 6 min (e.g., 5 minutes), but has a high adenoma detection rate (e.g., 35% of screening colonoscopy patients are found to have at least one adenoma), then withdrawal time is not a helpful indicator of quality. Similarly, if an endoscopist has a mean withdrawal time > 6 min (e.g., 9 minutes), but his/her adenoma detection rate is only 10%, then withdrawal time again is...
**C 2056 Colonoscopy Quality Index**

not a helpful indicator of quality.

8. **Free of Serious Complications**
   - Sufficient evidence has shown that most complications associated with colonoscopy (e.g., post-polypectomy bleeding) occur 1-14 days after the colonoscopy and are not captured by intra-procedural complication category. However, capturing complications that occur in the short period following the colonoscopy is also an important indicator of quality. In order to more accurately represent what this component measures, the Committee recommended that the title should be renamed to “Free of Serious Intra-Procedural Complications”.

9. **Appropriate Follow-up Recommendation**
   - The Committee agrees this is an important indicator of a quality colonoscopy. Multiple randomized control trials and endoscopic registry studies support current guideline recommendations for a repeat colonoscopy in the appropriate timeframe. Some studies have indicated that patients frequently get recommendations for a repeat colonoscopy that is not consistent with guidelines. It should be further addressed in the specifications when submitted for stage two review that recommendations for a repeat colonoscopy may not be provided to the patient at the time of the colonoscopy as it is often dependent on the results of the pathology results, which are usually available days after the procedure.

They further recommended that this composite be renamed to: Colonoscopy Quality Index for Colorectal Cancer Screening and Polyp Surveillance to better reflect its intent.

**Final Committee Votes:**

**Evidence:**

- **6:** Yes, with only these components included:
  - Item 1: Appropriate Indication for Colonoscopy
  - Item 4: Complete Examination
  - Item 5: Cecal Photo Taken
  - Item 6: All Essential Polyp Information Recorded
  - Item 8: Free of Serious Complications
  - Item 9: Appropriate Follow-up Recommendation

- **5:** Yes, as specified

- **3:** No

**Performance Gap:** H-9; M-2; L-1; I-2

**CSAC REVIEW (November 7-8, 2012)**

**Decision:** Approved as recommended by the Committee during the reconsideration and the amendment that the Steering Committee recommendations must be addressed prior to stage two submission. The concept for this composite was approved as follows:

- Item 1: Appropriate Indication for Colonoscopy
- Item 4: Complete Examination
- Item 5: Cecal Photo Taken
- Item 6: All Essential Polyp Information Recorded
- Item 8: Free of Serious Complications
- Item 9: Appropriate Follow-up Recommendation

**BOD REVIEW (November 29 – December 11, 2012)**

**Decision:** Ratification of the CSAC decision on concept approval.
## Measure Concept Submission Form

**Status:** New Submission

**Description:** Percentage of patients aged 18 years and older with a diagnosis of inflammatory bowel disease (IBD) who have been managed by corticosteroid* greater than or equal to 10mg/day for 60 or greater consecutive days that have been prescribed corticosteroid sparing therapy in the last reporting year.

**Numerator Statement:** Patients managed with corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days AND prescribed a corticosteroid sparing therapy (e.g. thiopurines, methotrexate, or anti-TNF agents).

**Denominator Statement:** All patients aged 18 years and older with a diagnosis of inflammatory bowel disease.

**Exclusions:** PQRS: Documentation of medical reason(s) for not treating with corticosteroid sparing therapy (e.g., toxicity, allergy, loss of effectiveness).

In the AGA Digestive Health Recognition Program (TM) because of the use of clinical data those that have not received a dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days are excluded from the denominator. We have also been able to include a patient exclusion for example if the patient refuses steroid sparing therapy.

**Adjustment/Stratification:**

**Level of Analysis:** Individual Clinician

**Type of Measure:** Process

**Data Source:** Electronic Clinical Data : Registry

**Measure Steward:** American Gastroenterological Association

### MEMBER COMMENTS (August 7-21, 2012)

- **America’s Health Insurance Plans** - This measure is appropriate for registry use as it is difficult to obtain data from other sources.
- **American College of Gastroenterology** - The College supports the measure in concept. However, we recommend that the measure developer provide clearer guidance on the denominator, and more specifically, the patient population excluded from the denominator. We also seek guidance on whether this measure is designed for only reporting quality measures via the Medicare Physician Quality Reporting System (PQRS) or when using the AGA Digestive Health Recognition Program as outlined in the submission.

In order to promote wide adoption of this measure and a clearer understanding of the relevant patient population in the denominator exclusions, we also recommend that for Stage 2 the measure developer provide a description that is without reference to PQRS or a specific registry, and instead, use common current procedural terminology (CPT) codes or specifications clearly outlining the relevant population. The College also recommends adding budesonide in the measure specifications as it is a steroid and should be included in a measure regarding corticosteroid sparing therapy.

### STEERING COMMITTEE MEETING (August 27-28, 2012)
C 2059 Inflammatory Bowel Disease (IBD) preventive care: corticosteroid sparing therapy

1. Importance to Measure and Report:

1a. High Impact: H-14; M-0; L-0; I-0

**Discussion:** There is general agreement this measure focus addresses a high impact area. IBD is a common problem and chronic use of steroids is a serious/complicated issue. Approximately 1.4 million in US population have IBD.

1c. Evidence

**14:** Yes, body of evidence meets guidance for quantity, quality, consistency

**Discussion:** The Committee agreed that the consistency of the evidence submitted is high, the quality is moderate and the quantity is high. This concept meets the evidence criterion.

**0:** No, body of evidence does not meet guidance for quantity, quality, consistency

**0:** No, inadequate information to rate quantity, quality, consistency of body of evidence

1b. Performance Gap: H-0; M-13; L-1; I-0

**Discussion:**
- In the data submitted, there was only a small study that demonstrated a performance gap. However, the Committee agreed that there is sufficient variation in clinical practice to warrant measurement.
- The data on racial disparities for this measure focus is more abundant; low SES patients do not generally have access to some of the alternative medications that can be cost prohibitive.
- The Committee agreed there is moderate gap in performance in this.

Recommendations to Developer for Stage 2:
- Re-examine exclusions and the denominator to ensure it clearly defined.
- It is questionable whether administrative claims can be used as a data source for this measure. To be effective, the denominator should include patients with IBD who are on chronic steroids; the Committee recognizes that the CPT-II codes that they have decided to use for the measures will make this difficult.
- Consider inclusions of patients on steroids for greater than 60 days in the numerator.
- Consider changing the denominator statement: add "AND on corticosteroids."
- Expand the denominator to include the pediatric population.
- Consider adding a component on whether a consult was made for surgery as a corticosteroid sparing therapy.
- Consider how patients who refuse treatment will be measured.
- Consider eMeasure specifications.
- Consider whether a more general measure focusing on long-term steroid therapy preventative care that would include components of C2062 (not recommended) would be more inclusive of care for this population.

Steering Committee Recommendation for Approval of Concept: Y-14; N-0

MEMBER & PUBLIC COMMENT (September 26 – October 25, 2012)

Member & Public Comments:
- No comments received.

CSAC REVIEW (November 7-8, 2012)
C 2059 Inflammatory Bowel Disease (IBD) preventive care: corticosteroid sparing therapy

**Decision:** Approved with the amendment that the Steering Committee recommendations must be addressed prior to stage two submission.

**BOD REVIEW (November 29 – December 11, 2012)**

**Decision:** Ratification of the CSAC decision on concept approval.
C 2065 Gastrointestinal Hemorrhage Mortality Rate (IQI #18)

Measure Concept Submission Form

Status: New Submission

Description: Percent of discharges with an in-hospital death among cases with a principal diagnosis of gastrointestinal hemorrhage

Numerator Statement: Number of in-hospital deaths among cases meeting the inclusion and exclusion rules for the denominator

Denominator Statement: All discharges, age 18 years and older, with a principal diagnosis code of gastrointestinal hemorrhage

Exclusions: Exclude cases:
- transferring to another short-term hospital
- MDC 14 (pregnancy, childbirth, and puerperium)
- with missing discharge disposition, gender, age, quarter, year or principal diagnosis

Adjustment/Stratification: The predicted value for each case is computed using a two-stage hierarchical model (the first stage is a logistic regression using Generalized Estimating Equations (GEE) to account for clustering of patients within hospitals; the second stage is a reliability weight). The covariates in the logistic regression include age (in 5-year age groups pooled), APR-DRG and APR-DRG Risk of Mortality subclass, MDC and transfer-in status. The reference population used in the regression is the universe of discharges for states that participate in the HCUP State Inpatient Data (SID) for the years 2008, a database consisting of 42 states and approximately 30 million adult discharges.

INTERCEPT
AGE 18 to 59
AGE 65+
APR-DRG '2201' (e.g., APR-DRG 220, Risk of Mortality level 1)
APR-DRG '2202' (e.g., APR-DRG 220, Risk of Mortality level 2)
APR-DRG '2203' (e.g., APR-DRG 220, Risk of Mortality level 3)
APR-DRG '2204' (e.g., APR-DRG 220, Risk of Mortality level 4)
APR-DRG '2211'
APR-DRG '2212'
APR-DRG '2213'
APR-DRG '2214'
APR-DRG '2411' to '2413'
APR-DRG '2414'
APR-DRG '2421' to '2423'
APR-DRG '2424'
APR-DRG '2441' to '2442'
APR-DRG '2443'
APR-DRG '2444'
APR-DRG '2532'
APR-DRG '2533'
APR-DRG '2541' to '2534'
APR-DRG '2544'
MDC Other
TRNSFER Transfer-in

Detailed risk model available at
C 2065 Gastrointestinal Hemorrhage Mortality Rate (IQI #18)

Level of Analysis: Facility
Type of Measure: Outcome
Data Source: Administrative claims
Measure Steward: Agency for Healthcare Research and Quality

MEMBER COMMENTS (August 7-21, 2012)

America's Health Insurance Plans - This measure may be subject to a small numbers problem raising reliability issues.

STEERING COMMITTEE MEETING (August 27-28, 2012)

1. Importance to Measure and Report:

1a. High Impact: H-14; M-0; L-0; I-0
   Discussion: There is general agreement this measure focus addresses a high impact area. GI hemorrhage is a common problem.

1c. Evidence
   14: Yes, body of evidence meets guidance for quantity, quality, consistency
   Discussion: Outcome measures do not require evidence; however, the Committee agreed that the developer did provide a rationale that supports the relationship of the health outcome to processes or structures of care.
   0: No, body of evidence does not meet guidance for quantity, quality, consistency
   0: No, inadequate information to rate quantity, quality, consistency of body of evidence

1b. Performance Gap: H-10; M-4; L-0; I-0
   Discussion:
   • The odds ratio of bleeding ranges from 17 to 22 based on the type of hospital and from 14 to 25 based on insurance status.
   • Risk adjusted using 3M APR-DRG's and it is publicly available to implement this measure. While gender is included in the risk adjustment model, race and ethnicity are not. This allows for stratification by race and ethnicity as the data submitted demonstrates significant differences in the outcomes among white, black, and hispanic patients.
   • The Committee agreed based on the above discussions, that there is a performance gap for this measure focus.

Recommendations to Developer for Stage 2:
• Numerator and denominator only include patients with primary diagnosis of GI bleed, consider how this might impact the capture of other patients with GI bleed who do not have it has a primary diagnosis.
• Consider stratifying by esophageal bleeds and lower GI bleeds.

Steering Committee Recommendation for Approval of Concept: Y-14; N-0

MEMBER & PUBLIC COMMENT (September 26 – October 25, 2012)

Member & Public Comments:
• One comment in support of this concept.
<table>
<thead>
<tr>
<th>C 2065 Gastrointestinal Hemorrhage Mortality Rate (IQI #18)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CSAC REVIEW (November 7-8, 2012)</strong></td>
</tr>
<tr>
<td><strong>Decision:</strong> Approved with the amendment that the Steering Committee recommendations must be addressed prior to stage two submission.</td>
</tr>
<tr>
<td><strong>BOD REVIEW (November 29 – December 11, 2012)</strong></td>
</tr>
<tr>
<td><strong>Decision:</strong> Ratification of the CSAC decision on concept approval.</td>
</tr>
<tr>
<td>Measure Concept Submission Form</td>
</tr>
<tr>
<td>--------------------------------</td>
</tr>
<tr>
<td><strong>Status:</strong> New Submission</td>
</tr>
<tr>
<td><strong>Description:</strong> Percentage of female patients with a characterization of the degree of prolapse in each vaginal compartment, using a validated, objective measurement system (e.g. POP-Q or Baden/Walker) within 12 months of surgery for pelvic organ prolapse.</td>
</tr>
<tr>
<td><strong>Numerator Statement:</strong> The number of female patients whose pelvic organ prolapse was documented using a validated, objective measurement tool (i.e. POP-Q or Baden/Walker Halfway System) performed within the 12 months prior to surgery for pelvic organ prolapse.</td>
</tr>
<tr>
<td><strong>Denominator Statement:</strong> All patients undergoing pelvic organ prolapse (POP) surgery.</td>
</tr>
<tr>
<td><strong>Exclusions:</strong> There are no exclusions.</td>
</tr>
<tr>
<td><strong>Adjustment/Stratification:</strong> We do not plan to risk adjust the measure. We do not plan to stratify the measure results.</td>
</tr>
<tr>
<td><strong>Level of Analysis:</strong> Clinician Group/Practice, Individual Clinician</td>
</tr>
<tr>
<td><strong>Type of Measure:</strong> Process</td>
</tr>
<tr>
<td><strong>Data Source:</strong> Administrative claims, Paper Medical Records</td>
</tr>
<tr>
<td><strong>Measure Steward:</strong> American Urogynecologic Society</td>
</tr>
</tbody>
</table>

**MEMBER COMMENTS (August 7-21, 2012)**

*America's Health Insurance Plans* - We are concerned that this measure does not meet the importance criterion as it does not focus on a demonstrated high-impact aspect of healthcare. While we recognize that this measure is designed to assess appropriateness of care, we believe better measures of appropriateness that are not clinical processes of care measures need to be developed. This measure will also require burdensome chart abstraction.

**STEERING COMMITTEE MEETING (August 27-28, 2012)**
C 2037 Objective characterization of pelvic organ prolapse prior to surgery

1. Importance to Measure and Report:

1a. High Impact: H-9; M-5; L-0; I-0

**Discussion:** The Committee agreed that characterizing the type of prolapse does impact the type of surgery that should be performed. There is general agreement this is a high impact measure focus.

1c. Evidence

1: Yes, body of evidence meets guidance for quantity, quality, consistency

12: No, body of evidence does not meet guidance for quantity, quality, consistency

**Discussion:**

- The evidence submitted for this concept does not specifically address the measure focus. Evidence is high quality but addresses the tools suggested by the measures not the actual characterization. The Committee agreed that there is no evidence to support this measure focus.

- *There is an exceptional and compelling reason that the measure should be considered further (i.e., benefits outweigh the harms): Y-3; N-11

1: No, inadequate information to rate quantity, quality, consistency of body of evidence

1b. Performance Gap:

**Discussion:** There was no discussion of gap as the concept did not pass evidence.

Recommendations to Developer:

- For future submissions on this topic, identify more evidence to suggest improper characterization results in poorer outcomes.
- There is opportunity for a better measure that is more proximal to the outcome. Consider developing an outcome measure of appropriateness of the surgery and patient reported improvement in outcomes.

Steering Committee Recommendation for Approval of Concept:

**Discussion:** This concept is not recommended for approval. The concept did not pass the evidence criterion.

MEMBER & PUBLIC COMMENT (September 26 – October 25, 2012)

**Member & Public Comments:**

- Commenters supported the measure focus, noting that failure to identify, and treat, all prolapsed compartments is considered a significant factor in the relatively high rate of failure in some prolapse surgeries.
- Commenters asked that the Committee reconsider the importance of the POP-Q tool in the importance of POP in characterization and surgical outcomes. The POP-Q has been the standard in objective characterization of pelvic organ prolapse.

**Committee response:**

- The Steering Committee agrees that this measure focus is a high impact area of measurement; however, the measure submitted for consideration did not meet the criteria for evidence. The Committee encourages further measure development that is more proximal to patient outcomes and supported by the evidence.
Measure Concept Submission Form

**Status:** New Submission

**Description:** Percentage of female patients who had SUI surgery and who received a complete workup assessing stress urinary incontinence and for whom SUI is objectively demonstrated within 12 months prior to surgery

**Numerator Statement:** Female patients who received the following as part of their complete workup within 12 months prior to surgery:
- Characterization of incontinence: focused history (questions asked of patient: duration of incontinence; number of episodes; use of protective products; i.e. "bother")
- Focused physical exam;
- Objective demonstration of stress incontinence;
- Post void residual analysis;
- Urinary analysis and urine culture, if indicated

**Denominator Statement:** All female patients who had SUI surgery without concomitant surgery for prolapse.

Patients with concomitant surgery for prolapse were excluded from the denominator because these measures are based on the AUA SUI guidelines which focused on an index patient without concomitant prolapse surgery. Prolapse surgery patients complicate the interpretation of the quality measures for SUI surgery such as characterization of prolapse symptoms, documentation of the involved compartments, and the severity of prolapse of each of the compartments as part of the physical exam. These elements are not necessary for stress incontinence patients. Prolapse patients should be excluded prior to SUI surgery to avoid potential complications.

**Exclusions:** Documentation of medical reason(s) for not performing a complete workup for assessment of stress urinary incontinence (such as prolapse; cognitive impairment limiting characterization of SUI--information might be obtained via caregiver).

**Adjustment/Stratification:**

<table>
<thead>
<tr>
<th>Level of Analysis</th>
<th>Type of Measure</th>
<th>Data Source</th>
<th>Measure Steward</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual Clinician</td>
<td>Process</td>
<td>Administrative claims, Paper Medical Records</td>
<td>American Urological Association</td>
</tr>
</tbody>
</table>

**MEMBER COMMENTS (August 7-21, 2012)**

*America's Health Insurance Plans* - This measure is not easily collected through administrative data and will require burdensome chart abstraction.

**STEERING COMMITTEE MEETING (August 27-28, 2012)**
**C 2049 Complete Workup for Assessment of Stress Urinary Incontinence (SUI) Prior to Surgery**

1. **Importance to Measure and Report:**

1a. **High Impact:** H-13; M-2; L-0; I-0  
   **Discussion:** There is general agreement this measure focus addresses a high impact area.

1c. **Evidence**

   0: Yes, body of evidence meets guidance for quantity, quality, consistency  
   4: No, body of evidence does not meet guidance for quantity, quality, consistency  
   **Discussion:**  
   - There are a few studies to support this measure focus. There will not likely be a randomized control trial to support this assessment measure as it is already accepted as a standard of care based on consensus.  
   - There is no empirical evidence to support the measure focus.  
   11: No, inadequate information to rate quantity, quality, consistency of body of evidence  
   **Discussion:**  
   - There were a couple studies identified by a Committee member, not cited by the developer, which support the use of pre-surgical assessments and linked to surgical outcomes.  
   - *There an exceptional and compelling reason that the measure should be considered further (i.e., benefits outweigh the harms): Y-15; N-0*  
   **Discussion:**  
   - The Committee ultimately agreed that there is insufficient evidence to support the measure focus but the benefits clearly outweigh the harms so agreed that the evidence subcriterion was met.

1b. **Performance Gap:** H-0; M-13; L-2; I-0  
   **Discussion:**  
   - The data submitted for the performance gap was not directly related to the five items specified in the numerator.  
   - The Committee agreed these items are standards of care and questioned whether it warrants a national consensus standard with this focus. The Committee ultimately agreed there is sufficient data to support a performance gap.

**Recommendations to Developer for Stage 2:**
- Reconsider the exclusions specified in this concept: excluding people for medical reasons or for cognitive impairment are not reasons for not having a work up.  
- Combine with C 2050 to include both components of care in the numerator for the same population in the denominator.

**Steering Committee Recommendation for Approval of Concept:** Y-15; N-0  
**Discussion:** While the Committee struggled to discern the link between completing an assessment and performing the appropriate surgery or better outcomes, they did agree that an assessment to determine the type of incontinence is important to selecting the right type of surgery for a patient. This concept was recommended for approval.
### C 2049 Complete Workup for Assessment of Stress Urinary Incontinence (SUI) Prior to Surgery

**Member & Public Comment included:**
- Commenters were concerned that measure might not be meaningful and should be paired with an outcome measure.
- Concerns were raised that the measure is simply recording what should be a standard practice and the exemption for documentation of results leaves too much room for manipulation of the results.
- It is unclear how the use of CPT codes will accurately account for objective documentation of urine leakage in all the settings where urodynamics are not done. This would bias the measure towards those clinicians who do urodynamic testing.
- Under use and premature surgical intervention without adequate pre-operative evaluation is a more significantly and costly problem than the overuse this measure seeks to address.

**Developer response:**
- The measure specifies that SUI needs to be objectively demonstrated. This includes demonstration of SUI on pelvic exam (i.e., office stress test), or urodynamic testing. Urodynamic testing is not required to meet the measure specifications. Instead, it is one tool that can be employed to objectively demonstrate SUI. Therefore, CPT codes alone cannot be utilized to determine compliance with the measure. In fact, the performance of urodynamic testing by itself does not guarantee that SUI was objectively demonstrated. The AUA envisions that this measure would be reported via a G-code, and that record review would be required in order to audit the data.

**Committee response:**
- The committee agrees that manipulation of results through gaming is a concern; however, the specific medical reason for the exclusion must be documented through the use of CPT-II codes. The Committee recommends that the specifications for the exclusions include a specific list of the types of medical reasons that are acceptable for this exclusion when the measures are submitted for the Stage 2 measure evaluation.

### CSAC REVIEW (November 7-8, 2012)

**Decision:** This concept was not recommended for approval due to concerns with lack of evidence linking the concepts to outcomes and lack of importance to the overall measure portfolio.
<table>
<thead>
<tr>
<th>Measure Concept Submission Form</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status:</strong> New Submission</td>
</tr>
<tr>
<td><strong>Description:</strong> Percentage of female patients who had SUI surgery for whom there was documentation that treatment options were discussed with the patient, including behavioral and surgical treatments, and expectations for treatment (discuss cure/dry rates)</td>
</tr>
<tr>
<td><strong>Numerator Statement:</strong> Female patients who had SUI surgery for whom there was documentation that treatment options were discussed with the patient, including behavioral and surgical, and expectations for treatment (discuss cure/dry rates)</td>
</tr>
<tr>
<td><strong>Denominator Statement:</strong> Female patients who had SUI surgery (without concomitant surgery for prolapse)</td>
</tr>
<tr>
<td><strong>Exclusions:</strong> Documentation of medical reason(s) for not counseling patient (e.g. patients who had concomitant prolapse or who are severely cognitively impaired). Documentation of patient reason(s) for not counseling patient (patients who might be uncomfortable with the responsibility of making choices regarding their care).</td>
</tr>
<tr>
<td><strong>Adjustment/Stratification:</strong></td>
</tr>
<tr>
<td><strong>Level of Analysis:</strong> Individual Clinician</td>
</tr>
<tr>
<td><strong>Type of Measure:</strong> Process</td>
</tr>
<tr>
<td><strong>Data Source:</strong> Administrative claims, Paper Medical Records</td>
</tr>
<tr>
<td><strong>Measure Steward:</strong> American Urological Association</td>
</tr>
</tbody>
</table>

**MEMBER COMMENTS (August 7-21, 2012)**

*America’s Health Insurance Plans* - This measure assesses standard practice and it would be difficult to assess how well counseling is performed.

**STEERING COMMITTEE MEETING (August 27-28, 2012)**
C 2050 Patient counseling on treatment options, including behavioral and surgical treatments prior to Stress Urinary Incontinence (SUI) surgery

1. Importance to Measure and Report:

1a. High Impact: H-12; M-3; L-0; I-0

Discussion: There is general agreement this measure focus addresses a high impact area.

1c. Evidence

3: Yes, body of evidence meets guidance for quantity, quality, consistency
3: No, body of evidence does not meet guidance for quantity, quality, consistency
9: No, inadequate information to rate quantity, quality, consistency of body of evidence

Discussion:
- Guidelines were submitted from European and US guidelines, but there was no direct evidence submitted to support that counseling will improve outcomes for women with SUI.
- This concept represents the standard of care. The Committee discussed whether this focus area is worthy of a national quality measure.
- They also discussed the ability for surgeons to game the system and document they counseled when they in fact did not counsel patients on treatment options.
- There is, however, a large body of evidence about shared decision making that suggest that when you counsel patients in general it leads to better outcomes; this general body of evidence would apply and support this specific measure focus.
- The Committee agreed that the information exists, but it was not provided in the measure submission.
- There is general agreement that the quantity, quality, and consistency of the body of evidence meet the NQF guidance: Y-15; N-0

1b. Performance Gap: H-3; M-11; L-1; I-0

Discussion:
- While the data presented does not represent of the gap in the US population, the Committee agreed based on clinical experience that patient expectations for surgery are often not representative of actual cure rates.

Recommendations to Developer for Stage 2:
- Reconsider the exclusions specified in this concept: excluding people for medical reasons or for cognitive impairment are not reasons for not having a work up.
- Patient reasons for not counseling are not precise.
- Recommend eMeasure specifications.
- Combine with C 2049 to include both components of care in the numerator for the same population in the denominator.
- Potential risks and treatment options discussed should be broadened to include biofeedback, medications, and especially the use of surgical mesh.

Steering Committee Recommendation for Approval of Concept: Y-15; N-0

MEMBER & PUBLIC COMMENT (September 26 – October 25, 2012)
**Member & Public Comments:**

- Commenters were concerned that measure might not be meaningful and should be paired with an outcome measure.
- Concerns were raised that this measure is solely a documentation measure without specifications for how it would capture the actual quality of the counseling process. Shared decision-making must go beyond just discussing treatment options. This includes whether there was information about benefits and harms of options, the patient’s understanding of options and treatment effects, whether the patient's value and preferences were identified, and whether there was concordance of the decision and care received with those values and preferences.
- A more meaningful measure of patient counseling on treatment options would be captured by patient-reported data.

**Developer response:**

- The AUA agrees that the quality of decision-making is important in deciding on surgery for SUI. The intent of this measure is to document that all treatment options (including nonsurgical treatment options) were discussed with patients before surgery. As the comment highlights, the quality of the decision-making process is multifactorial and complex, and includes many factors which are difficult to measure.

**Committee response:**

- The Committee agrees that capturing the patient’s experience is an important aspect of measurement in counseling measures and considers these measures to be good start towards evaluating shared decision making because it reinforces the physician’s responsibility to discuss treatment options. Measure 0030 already captures the patient experience via the survey tool; however, the quality of this discussion and how it impacts the patient’s response may be best captured in a patient-reported outcome measure.

---

**CSAC REVIEW (November 7-8, 2012)**

**Decision:** This concept was not recommended for approval due to concerns with lack of evidence linking the concepts to outcomes and lack of importance to the overall measure portfolio.
### Measure Concept Submission Form

<table>
<thead>
<tr>
<th><strong>Measure Concept Submission Form</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status:</strong> New Submission</td>
</tr>
<tr>
<td><strong>Description:</strong> Percentage of female patients who undergo mesh sling surgery for whom there was documentation that they were counseled about the risks associated with the use of mesh in sling surgery (erosion/extrusion, pain, permanence) prior to surgery</td>
</tr>
<tr>
<td><strong>Numerator Statement:</strong> Female patients who undergo mesh sling surgery for whom there was documentation that they had been counseled about the risk of mesh erosion/extrusion, pain, and permanence prior to performing a mesh sling surgery</td>
</tr>
<tr>
<td><strong>Denominator Statement:</strong> All female patients who undergo mesh sling surgery (without concomitant surgery for prolapse)</td>
</tr>
<tr>
<td><strong>Exclusions:</strong> Documentation of medical reason(s) for not performing a complete workup for assessment of stress urinary incontinence (such as use of a nonsynthetic material for the sling; concomitant prolapse; cognitive impairment limiting characterization of SUI--information might be obtained via caregiver).</td>
</tr>
<tr>
<td><strong>Adjustment/Stratification:</strong></td>
</tr>
<tr>
<td><strong>Level of Analysis:</strong> Individual Clinician</td>
</tr>
<tr>
<td><strong>Type of Measure:</strong> Process</td>
</tr>
<tr>
<td><strong>Data Source:</strong> Administrative claims, Paper Medical Records</td>
</tr>
<tr>
<td><strong>Measure Steward:</strong> American Urological Association</td>
</tr>
</tbody>
</table>

### MEMBER COMMENTS (August 7-21, 2012)

*America’s Health Insurance Plans* - This is a process measure and assesses documentation of patient counseling. This measure cannot be easily collected through administrative data and will require burdensome chart abstraction.

### STEERING COMMITTEE MEETING (August 27-28, 2012)
C 2051 Patients Counseled About Risks Associated with the Use of Mesh in Sling Surgery Prior to Surgery

1. Importance to Measure and Report:

1a. High Impact: H-9; M-3; L-2; I-1
   **Discussion:** The Committee agreed this concept meets the criterion for high impact.

1c. Evidence
   5: Yes, body of evidence meets guidance for quantity, quality, consistency
   7: No, body of evidence does not meet guidance for quantity, quality, consistency
   **Discussion:**
   - The evidence submitted was not linked to the measure focus of counseling, but rather the outcomes associated with the use of mesh. In addition to the US FDA warning, most of the evidence is European. The data collection for this measure would overlap with the informed consent process for this surgery.
   - The Committee discussed the link between counseling and decreasing sling surgeries or erosions.
   - The risks of using mesh is clearly important, but since the denominator for this concept only includes patients who have had the surgery, the desired outcome to decrease mesh surgeries and complications is not captured with this measure.
   - The Committee agreed the evidence does not exist to support the measure focus (i.e., no empirical evidence).
   - There is an exceptional and compelling reason that the measure should be considered further (i.e., benefits outweigh the harms): Y-4; N-11

1b. Performance Gap:
   **Discussion:** There was no discussion of gap as the measure did not pass evidence.

Recommendations to Developer:
- Consider combining this measure with one of the other similar measures where there is a broader denominator that is not limited to patients who have already had the mesh surgery.

Steering Committee Recommendation for Approval of Concept:
**Discussion:** This concept is not recommended for approval. The concept did not pass the evidence criterion.

**MEMBER & PUBLIC COMMENT (September 26 – October 25, 2012)**

Member & Public Comments:
- No comments received.
### C 2054 Assessment of treatment within one year of Stress Urinary Incontinence (SUI) surgery

**Measure Concept Submission Form**

**Status:** New Submission

**Description:** Percentage of female patients who had SUI surgery, who had an assessment of response to surgical treatment performed within 1 year post-surgery

**Numerator Statement:** Female patients without concomitant prolapse who had SUI surgery and who received the following as part of their postoperative assessment within one year:

- Characterization of incontinence: focused history (questions asked of patient: duration of incontinence; number of episodes; use of protective products, i.e. “bother”)
- Focused physical exam
- Post void residual analysis
- Urinary analysis, and urinary culture, if indicated

**Denominator Statement:** Female patients who had SUI surgery without concomitant surgery for prolapse seen at follow up within one year post-treatment

Patients with concomitant surgery for prolapse were excluded from the denominator because these measures are based on the AUA SUI guidelines which focused on an index patient without concomitant prolapse surgery. Prolapse surgery patients complicate the interpretation of the quality measures for SUI surgery such as characterization of prolapse symptoms, documentation of the involved compartments, and the severity of prolapse of each of the compartments as part of the physical exam. These elements are not necessary for stress incontinence patients.

**Exclusions:** Documentation of medical reason(s) for not performing all or one of these elements (concomitant prolapse).

Documentation of patient reason(s) for not performing all or one of these elements (inability to make and keep an appointment with the treating physician due to relocation, incapacity, and inability to travel).

Documentation of system reason(s) for not performing all or one of these elements (visits are not reimbursable by the patient’s insurer)

**Adjustment/Stratification:**

**Level of Analysis:** Individual Clinician

**Type of Measure:** Process

**Data Source:** Administrative claims, Paper Medical Records

**Measure Steward:** American Urological Association

### MEMBER COMMENTS (August 7-21, 2012)

*America’s Health Insurance Plans:* We are concerned that this is already the standard of care patients should be receiving. We recommend revising the exclusionary criteria so that patients whose visits are not reimbursable by an insurer are captured in the denominator. Follow-up visits are often included in the package of services for which insurers make a bundled payment.

### STEERING COMMITTEE MEETING (August 27-28, 2012)
### C 2054 Assessment of treatment within one year of Stress Urinary Incontinence (SUI) surgery

#### 1. Importance to Measure and Report:

1a. High Impact: H-2; M-7; L-4; I-1
   **Discussion:** The Committee agreed this concept meets the criterion for high impact.

1c. Evidence
   
   **0:** Yes, body of evidence meets guidance for quantity, quality, consistency
   **13:** No, body of evidence does not meet guidance for quantity, quality, consistency
   
   **Discussion:**
   - There was no evidence submitted. The evidence section of this submission form was incomplete and did not list any guidelines or evidence to support the measure focus. The Committee experts were unable to identify any significant literature or evidence to support this measure focus.
   - *There is an exceptional and compelling reason that the measure should be considered further (i.e., benefits outweigh the harms): Y-4; N-10*
   
   **1:** No, inadequate information to rate quantity, quality, consistency of body of evidence

1b. Performance Gap:
   **Discussion:** There was no discussion of gap as the measure did not pass evidence.

#### Recommendations to Developer:

- The time period for this measure is a concern; day 1 to 365 is too wide.
- Consider another measure that focuses on the desired outcome related to this measure focus or a process that is linked closer to the desired outcome. The collection of more data points related to complications would make it more useful.

#### Steering Committee Recommendation for Approval of Concept:

**Discussion:** This concept is not recommended for approval. The concept did not pass the evidence criterion.

### MEMBER & PUBLIC COMMENT (September 26 – October 25, 2012)

**Member & Public Comments:**

- No comments received.
C 2062 Inflammatory Bowel Disease (IBD) preventive care: corticosteroid related iatrogenic injury – bone loss assessment

Measure Concept Submission Form

**Status:** New Submission

**Description:** Percentage of patients aged 18 years and older with a diagnosis of inflammatory bowel disease who have received dose of corticosteroids greater than or equal to 10 mg/day for 60 or greater consecutive days were assessed for risk of bone loss once per the reporting year.

**Numerator Statement:** Patients who have received dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days who were assessed for risk of bone loss.

**Denominator Statement:** All patients aged 18 years and older with a diagnosis of inflammatory bowel disease.

**Exclusions:** There are no exclusions as specified for PQRS purposes.
In the AGA Digestive Health Recognition Program (TM) because of the use of clinical data those that have not received a dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days are excluded from the denominator.

**Adjustment/Stratification:**

**Level of Analysis:** Clinician : Individual

**Type of Measure:** Process

**Data Source:** Electronic Clinical Data : Registry

**Measure Steward:** American Gastroenterological Association

**MEMBER COMMENT (August 7-21, 2012)**

None

**STEERING COMMITTEE MEETING (August 27-28, 2012)**

1. Importance to Measure and Report:

1a. High Impact: H-0; M-14; L-0; I-0

   **Discussion:** There was general agreement that this measure focus has a moderate impact. The data submitted for this criterion only cited information from the United Kingdom and Canada.

1c. Evidence

   1: Yes, body of evidence meets guidance for quantity, quality, consistency
   5: No, body of evidence does not meet guidance for quantity, quality, consistency
   8: No, inadequate information to rate quantity, quality, consistency of body of evidence

   **Discussion:**
   - There is no evidence to suggest that performing this test actually improves outcomes. There were only two population-based studies cited. The quantity rating would be closer to moderate, but there is insufficient information to rate quality and consistency. The Committee agreed there is no evidence to support this measure focus.
   - *There is general agreement that the quantity, quality, and consistency of the body of evidence meet the NQF guidance:* Y-0; N-14

1b. Performance Gap:

   **Discussion:** There was no discussion of gap as the measure did not pass evidence.
### C 2062 Inflammatory Bowel Disease (IBD) preventive care: corticosteroid related iatrogenic injury – bone loss assessment

**Recommendations to Developer:**
- Further information on the evidence to support this concept is needed.
- Consider whether a more general measure focusing on long-term steroid therapy preventative care that would include components of C2059 (recommended) would be more inclusive of care for this population. Again, more evidence would be required to support the bone loss assessment portion of the concept.

**Steering Committee Recommendation for Approval of Concept:**

**Discussion:** This concept is not recommended for approval. The concept did not pass the evidence criterion.

**MEMBER & PUBLIC COMMENT (September 26 – October 25, 2012)**

**Member & Public Comments:**
- No comments received.
Appendix A: Concept Specifications

0030 Urinary Incontinence Management in Older Adults - a. Discussing urinary incontinence, b. Receiving urinary incontinence treatment – A patient reported measure ................................................................. 58

0098 Urinary Incontinence: Assessment, Characterization, and Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older – an administrative measure ........................................................................... 59

0622 GERD - Upper Gastrointestinal Study in Adults with Alarm Symptoms ................................................................. 61

0635 Chronic Liver Disease - Hepatitis A Vaccination ........................................................................................................ 63

0658 Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients ....................................................................................................................... 65

0659 Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps- Avoidance of Inappropriate Use ....................................................................................................... 68

C 2038 Performing vaginal apical suspension (uterosacral, iliococcygeus, sacrospinous or sacral colpopexy) at the time of hysterectomy to address uterovaginal prolapse ........................................................................ 70

C 2052 Reduction of Complications through the use of Cystoscopy during Surgery for Stress Urinary Incontinence ........................................................................................................................................ 71

C 2056 Colonoscopy Quality Index ..................................................................................................................................... 72

C 2059 IBD preventive care: corticosteroid sparing therapy .............................................................................................. 75

C 2063 Use of cystoscopy concurrent with prolapse repair surgery .................................................................................. 76

C 2065 Gastrointestinal Hemorrhage Mortality Rate (IQI #18) ....................................................................................... 77
<table>
<thead>
<tr>
<th><strong>0030 Urinary Incontinence Management in Older Adults - a. Discussing urinary incontinence, b. Receiving urinary incontinence treatment – A patient reported measure</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status</strong></td>
</tr>
<tr>
<td><strong>Steward</strong></td>
</tr>
<tr>
<td><strong>Description</strong></td>
</tr>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
</tr>
<tr>
<td><strong>Level</strong></td>
</tr>
<tr>
<td><strong>Setting</strong></td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
</tr>
<tr>
<td><strong>Numerator Details</strong></td>
</tr>
<tr>
<td><strong>Denominator Statement</strong></td>
</tr>
</tbody>
</table>
### 0030 Urinary Incontinence Management in Older Adults - a. Discussing urinary incontinence, b. Receiving urinary incontinence treatment – A patient reported measure

| Denominator Details | Time Window: Measurement Year.  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Member choices must be as follows to be included in the denominator:</td>
</tr>
<tr>
<td></td>
<td>Q1= Many people experience problems with urinary incontinence, the leakage of urine. In the past 6 months, have you accidentally leaked urine? Answer= “Yes”</td>
</tr>
<tr>
<td></td>
<td>Q2= How much of a problem, if any, was the urine leakage for you? Answer= “A big problem” or “a small problem” (Note: Patients who “not a problem” are not included in the measure denominator).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusions</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Details</td>
<td>N/A</td>
</tr>
<tr>
<td>Risk Adjustment</td>
<td>No risk adjustment or risk stratification</td>
</tr>
<tr>
<td>Stratification</td>
<td>N/A</td>
</tr>
</tbody>
</table>
| Copyright/Disclaimer | © 2012 by the National Committee for Quality Assurance  
1100 13th Street, NW, Suite 1000  
Washington, DC 20005  
N/A |

### 0098 Urinary Incontinence: Assessment, Characterization, and Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older – an administrative measure

<table>
<thead>
<tr>
<th>Status</th>
<th>Maintenance, Original Endorsement: May 01, 2007, Most Recent Endorsement: May 01, 2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steward</td>
<td>National Committee for Quality Assurance Other organizations: AMA-PCPI</td>
</tr>
</tbody>
</table>
| Description | This is a clinical performance measure which assesses whether women age 65+ were provided appropriate treatment for urinary incontinence (UI). This measure has three rates:  
(A) Assessment for UI: Percentage of female patients aged 65 years and older who were assessed for the presence or absence of urinary incontinence within 12 months.  
(B) Characterization of UI: Percentage of female patients aged 65 years and older with a diagnosis of urinary incontinence whose urinary incontinence was characterized at least once within 12 months.  
(C) Plan of Care for UI: Percentage of female patients aged 65 years and older with a diagnosis of urinary incontinence with a documented plan of care for urinary incontinence at least once within 12 months |
| Type | Process |
| Data Source | Administrative claims |
| Level | Clinician : Group/Practice, Clinician : Individual, Clinician : Team |
| Setting | Ambulatory Care : Clinician Office/Clinic |
| **Numerator Statement** | This measure has three rates. The numerator for each of the rates is as follows:
(A) Assessment for UI: Patients who were assessed for the presence or absence of urinary incontinence within 12 months
(B) Characterization of UI: Patients whose urinary incontinence was characterized at least once within 12 months
(C) Plan of Care for UI: Patients with a documented plan of care for urinary incontinence at least once within 12 months
Urinary incontinence is defined as any involuntary leakage of urine.
Characterization of urinary incontinence may include one or more the following: frequency, volume, timing, type of symptoms, and/or how bothersome to the patient
Plan of care may include behavioral interventions (e.g., bladder training, pelvic floor muscle training, prompted voiding), referral to specialist, surgical treatment, reassess at follow-up visit, lifestyle interventions, addressing co-morbid factors, modification or discontinuation of medications contributing to urinary incontinence, or pharmacologic therapy. |
| **Numerator Details** | Time Window: 1x within measurement year
The numerator for this measure is based on reporting CPT Category II codes. The codes for each rate numerator are as follows:
(A) Assessment of UI: 1090F - Presence or absence of urinary incontinence assessed
(B) Characterization of UI: 1091F - Urinary incontinence characterized
(C) Plan of Care for UI: 0509F - Urinary incontinence plan of care documented |
| **Denominator Statement** | There are two denominators for the rates in this measure.
(A) Assessment of UI: All female patients aged 65 years and older who visited and eligible provider in the measurement year
(B&C) Characterization and Plan of Care for UI: All female patients aged 65 years and older with a diagnosis of urinary incontinence who visited an eligible provider in the measurement year. |
| **Denominator Details** | Time Window: 12 month measurement period
The denominator for rate (A) Assessment of UI, is based on office visits to an eligible provider. CPT codes are used to identify female patients age 65 + with an office visit to an eligible provider.
The denominator for rates (B&C) Characterization and Plan of Care for UI, is based on office visits and a documented diagnosis using ICD-9 codes.
(A) Assessment of UI:
CPT codes:
99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, 99245, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99387, 99397, 99401, 99402, 99403, 99404
(B&C) Characterization & Plan of Care:
ICD-9 diagnosis codes
307.6, 625.6, 788.30, 788.31, 788.33, 788.34, 788.35, 788.36, 788.37, 788.38, 788.39
AND
CPT service codes
99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, 99245, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99387, 99397, 99401, 99402, 99403, 99404 |
<table>
<thead>
<tr>
<th><strong>0098 Urinary Incontinence: Assessment, Characterization, and Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older – an administrative measure</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exclusions</strong></td>
</tr>
<tr>
<td><strong>Exclusion Details</strong></td>
</tr>
<tr>
<td><strong>Risk Adjustment</strong></td>
</tr>
<tr>
<td><strong>Stratification</strong></td>
</tr>
<tr>
<td><strong>Copyright/Disclaimer</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>0622 GERD - Upper Gastrointestinal Study in Adults with Alarm Symptoms</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status</strong></td>
</tr>
<tr>
<td><strong>Steward</strong></td>
</tr>
<tr>
<td><strong>Description</strong></td>
</tr>
<tr>
<td><strong>Type</strong></td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
</tr>
<tr>
<td><strong>Level</strong></td>
</tr>
<tr>
<td><strong>Setting</strong></td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
</tr>
<tr>
<td><strong>0622 GERD - Upper Gastrointestinal Study in Adults with Alarm Symptoms</strong></td>
</tr>
<tr>
<td>---</td>
</tr>
</tbody>
</table>
| **Numerator Details** | Time Window: 12 months  
One of the following is correct  
a. Evidence of at least 1 esophageal procedure, upper GI study (Upper GI radiologic exam with high density barium, with or without delayed films, esophageal or gastric motility study, gastric emptying study, gastric analysis test, upper GI endoscopy, or upper GI series), or gastrectomy from claims or HIE in the past 12 months  
b. Evidence of at least 1 gastric or esophageal cancer diagnosis from claims or HIE in the past 12 months; note-cancer diagnosis implies diagnostic testing was done, and therefore completes numerator  
c. Presence of provider or patient feedback indicating that a GI Evaluation already implemented in the past 12 months.  
d. Presence of patient self-reported data confirming at least 1 EGD or Upper GI Study in past 12 months |
| **Denominator Statement** | Patients, 18 years and older, diagnosed with GERD with alarm symptoms (e.g., dysphagia, iron deficiency anemia, weight loss) |
| **Denominator Details** | Time Window: 12 months  
DENOMINATOR  
All of the following are correct:  
1. Age = 18 Years  
2. One of the following is correct:  
a. Presence of patient self-reported data, via PHR or telephonic nurse assessment in our disease management program, confirming they have GERD and GERD warning symptoms in the past 12 months  
b. All of the following are correct:  
i. Presence of at least 2 diagnosis codes from claims or 1 diagnosis code from HIE for GERD in the past 12 months  
ii. One of the following:  
A. At least 2 diagnosis codes from claims or 1 diagnosis code from HIE for weight loss in the past 12 months  
B. At least 2 diagnosis codes from claims or 1 diagnosis code from HIE for dysphagia in the past 12 months  
C. Patient data via feedback survey or PHR indicating that they have GERD with warning symptoms in the past 12 months  
iii. One of the Following are correct:  
A. Presence of at least 1 fill for a 60 total days supply of a PUD/GERD medication in the past 12 months from claims  
B. Presence of at least 1 fill for a PUD/GERD medication in the past 3 months from HIE |
| **Exclusions** | Specific Exclusions:  
1. Patients with a documented gastrointestinal malignancy  
2. Patients with other causes of the alarm symptoms including esophageal varices, known Barrett’s esophagus, or gastric restrictive procedures  
General Exclusions:  
Metastatic malignancy, chemotherapy/radiation therapy, hospice and Skilled Nursing Facility, feedback from physician indicating GI study contraindicated or not applicable. |
### 0622 GERD - Upper Gastrointestinal Study in Adults with Alarm Symptoms

**Exclusion Details**
- SPECIFIC DENOMINATOR EXCLUSIONS
  1. Presence of at least 2 diagnosis codes from claims or 1 diagnosis code from HIE for Barrett’s esophagus in the past 24 months
  2. Presence of at least 2 diagnosis codes from claims or 1 diagnosis code from HIE for esophageal varices in the past 24 months
  3. Presence of at least 2 diagnosis codes from claims or 1 diagnosis code from HIE for a gastrointestinal cancer in the past 24 months
  4. Presence of at least diagnosis code from claims or HIE for weight loss surgery or a gastric restrictive procedure anytime in the past

**Risk Adjustment**
- No risk adjustment or risk stratification

**Stratification**
- This measure is not stratified.

### 0635 Chronic Liver Disease - Hepatitis A Vaccination

**Status**
- Maintenance, Original Endorsement: Dec 04, 2009, Most Recent Endorsement: Dec 04, 2009

**Steward**
- ActiveHealth Management

**Description**
- The percentage of adult patients with chronic liver disease who have received a hepatitis A vaccine

**Type**
- Process

**Data Source**
- Administrative claims, Electronic Clinical Data, Electronic Clinical Data: Electronic Health Record, Healthcare Provider Survey, Electronic Clinical Data: Laboratory, Patient Reported Data/Survey, Electronic Clinical Data: Pharmacy Claims ingested via ActiveHealth Management’s rules engine, CareEngine. Electronic clinical data source for pharmacy, lab, and EHR data is ActiveCareTeam (clinical workflow tool and dashboard) and MyActiveHealth (PHR). Healthcare provider survey and patient survey included as a part of clinical alerts (aka Care Considerations) feedback section.

**Level**
- Population: National, Population: Regional

**Setting**
- Ambulatory Care: Clinician Office/Clinic, Home Health

**Numerator Statement**
- Patients with chronic liver disease who have received a hepatitis A vaccine or who have been tested for immunity in the past. Keeping in consideration that providers who test for Hepatitis A immunity most likely intend to take action on the test results and that hepatitis A testing is usually communicated in the form of LOINC codes which do not indicate immunity confirmed, immunity testing is considered sufficient for completion of the numerator for this measure.

**Numerator Details**
- Time Window: Anytime in the past
  - One of the following:
    1. At least 1 fill of Hepatitis A vaccine from claims or HIE anytime in the past
    2. At least 1 Hepatitis A vaccine procedure from claims or HIE anytime in the past
    3. At least 1 Hepatitis A antibody procedure from claims or HIE anytime in the past
    4. At least 1 Hepatitis A Lab result from claims or HIE anytime in the past
    5. Patient-reported data indicating that they received a Hepatitis A vaccine anytime in the past
<table>
<thead>
<tr>
<th>Denominator Statement</th>
<th>All patients, ages 18 and older, diagnosed with chronic liver disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denominator Details</td>
<td>Time Window: 12 months</td>
</tr>
<tr>
<td></td>
<td>All of the following:</td>
</tr>
<tr>
<td></td>
<td>1. Age ≥ 18 years</td>
</tr>
<tr>
<td></td>
<td>2. One of the following</td>
</tr>
<tr>
<td></td>
<td>a. One of the following</td>
</tr>
<tr>
<td></td>
<td>i. At least 2 diagnosis codes from claims or 1 diagnosis code from HIE for Chronic Hepatitis B in the past 24 months</td>
</tr>
<tr>
<td></td>
<td>ii. Patient self-reported data, via PHR or telephonic nurse assessment in our disease management program, confirming a diagnosis of Chronic Hepatitis B anytime in the past</td>
</tr>
<tr>
<td></td>
<td>iii. At least 2 hepatitis B surface or E antigen or DNA Labs Result Value &gt; 1 in the past 12 months from claims</td>
</tr>
<tr>
<td></td>
<td>iv. At least 2 diagnosis codes from claims for Chronic Hepatitis B anytime in the past with one of the following</td>
</tr>
<tr>
<td></td>
<td>A. At least 1 current fill of a Hepatitis B medication from HIE</td>
</tr>
<tr>
<td></td>
<td>B. At least 2 fills of a Hepatitis B medication from claims in the past 24 months</td>
</tr>
<tr>
<td></td>
<td>C. At least 2 procedure codes for Interferon therapy in the past 24 months from claims</td>
</tr>
<tr>
<td></td>
<td>b. One of the following</td>
</tr>
<tr>
<td></td>
<td>i. At least 2 diagnosis codes from claims or 1 diagnosis code from HIE for Chronic Hepatitis C in the past 24 months</td>
</tr>
<tr>
<td></td>
<td>ii. Patient self-reported data, via PHR or telephonic nurse assessment in our disease management program, confirming a diagnosis of Chronic Hepatitis C anytime in the past</td>
</tr>
<tr>
<td></td>
<td>iii. At least 1 hepatitis C antibody or RNA Labs Result Value &gt; 1 in the past 12 months</td>
</tr>
<tr>
<td></td>
<td>iv. Patient self-reported data, via PHR or telephonic nurse assessment in our disease management program, confirming a diagnosis of Chronic Hepatitis C anytime in the past</td>
</tr>
<tr>
<td></td>
<td>v. At least 2 diagnosis codes from claims for Chronic Hepatitis C anytime in the past with one of the following</td>
</tr>
<tr>
<td></td>
<td>A. At least 2 fills of a Hepatitis C medication from HIE</td>
</tr>
<tr>
<td></td>
<td>B. At least 2 fills of a Hepatitis C medication from claims in the past 24 months</td>
</tr>
<tr>
<td></td>
<td>C. At least 2 procedure codes for Hepatitis C treatment in the past 24 months from claims</td>
</tr>
<tr>
<td></td>
<td>D. At least 2 diagnosis codes from claims for chronic liver disease (excluding Hepatitis A) in the past 12 months</td>
</tr>
<tr>
<td>Exclusions</td>
<td>Patients with a previous history of viral hepatitis A. General exclusions: 1. Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months; 2. Patients who have been in a skilled nursing facility in the last 3 months (this exclusion is included to avoid holding physicians who care for patients during a transitional period, e.g. temporary SNF placement, for their ongoing care; hence, the time limitation of 3 months).</td>
</tr>
<tr>
<td>Exclusion Details</td>
<td>One of the following:</td>
</tr>
<tr>
<td></td>
<td>1. At least 1 diagnosis code for Hepatitis A infection from claims or HIE anytime in the past</td>
</tr>
<tr>
<td></td>
<td>2. Patient self-reported data, via PHR or telephonic nurse assessment in our disease management program, indicating that they are allergic to the Hepatitis A vaccine anytime in the past</td>
</tr>
<tr>
<td>Risk Adjustment</td>
<td>No risk adjustment or risk stratification</td>
</tr>
</tbody>
</table>
### 0635 Chronic Liver Disease - Hepatitis A Vaccination

**Stratification**
None

**Copyright/Disclaimer**
This information, including any attachments hereto, is the sole, exclusive, proprietary and confidential property of ActiveHealth Management, Inc., and is for the exclusive use of The National Quality Forum. Any use, copying, disclosure, dissemination or distribution by anyone other than the National Quality Forum is strictly prohibited.

### 0658 Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients

**Status**
Maintenance, Original Endorsement: Jan 17, 2011, Most Recent Endorsement: Jan 17, 2011

**Steward**
American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)
Other organizations: American Society for Gastrointestinal Endoscopy (ASGE)/American Gastroenterological Association (AGA)/National Committee for Quality Assurance

**Description**
Percentage of patients aged 50 years and older receiving a screening colonoscopy without biopsy or polypectomy who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report.

**Type**
Process

**Data Source**
Attachment AMA-PCPI_Measure Calculation-Standard Measures-634757781692493718-634759686421435928.pdf

**Level**
Clinician: Group/Practice, Clinician: Individual, Clinician: Team

**Setting**
Ambulatory Care: Ambulatory Surgery Center (ASC), Ambulatory Care: Clinician Office/Clinic

**Numerator Statement**
Patients who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report

**Numerator Details**
Time Window: Once for each screening colonoscopy performed during the measurement period
Patients will be counted in the numerator if there is reference in the final colonoscopy report that the appropriate follow-up interval for the next colonoscopy is at least 10 years from the date of the current colonoscopy (i.e., the colonoscopy performed during the measurement period). For claims specifications, a CPT Category II code will be reported for this measure. For EHR specifications, we will use SNOMED-CT to identify the information in the final colonoscopy report. In Stage 2 of this pilot, we will submit EHR specifications and claims specifications; the combination of the two types of specifications can be used for registry reporting. The data stream for registries can be claims, EHR or manual data entry.

**Denominator Statement**
All patients aged 50 years and older receiving screening colonoscopy without biopsy or polypectomy

**Denominator Details**
Time Window: Each procedure/diagnostic study performed during 12 consecutive months
The denominator of this measure includes patients at least 50 years of age who receive a screening colonoscopy during the measurement period. The denominator details will include the patient age criterion and applicable CPT, G-Codes and SNOMED-CT procedure codes for a screening colonoscopy. The procedures that will be identified include only those without biopsy or polypectomy, meaning the patient did not have any polyps removed or biopsied during the colonoscopy procedure. In Stage 2 of this pilot, we will submit EHR specifications and claims specifications.
### 0658 Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients

<table>
<thead>
<tr>
<th>Exclusions</th>
<th>Documentation of medical reason(s) for not recommending at least a 10 year follow-up interval (eg, above average risk patient, inadequate prep)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Details</td>
<td>The PCPI methodology uses three categories of reasons for which a patient may be excluded from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For measure 0658, exceptions may include medical reason(s) (eg, above average risk patient, inadequate prep) for not recommending at least a 10 year follow-up interval. Where examples of exceptions are included in the measure language, these examples are coded and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients’ medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician’s exceptions data to identify practice patterns and opportunities for quality improvement. For example, it is possible for implementers to calculate the percentage of patients that physicians have identified as meeting the criteria for exception. Additional information by data source includes: For claims specifications, a CPT Category II modifier will be reported by the physician to indicate the patient has an allowable exception for the measure. For EHR specifications, we will develop value sets for the examples provided in the measure.</td>
</tr>
<tr>
<td>Risk Adjustment</td>
<td>No risk adjustment or risk stratification Not applicable.</td>
</tr>
<tr>
<td>Stratification</td>
<td>We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.</td>
</tr>
<tr>
<td>Type Score</td>
<td>Rate/proportion  better quality = higher score</td>
</tr>
</tbody>
</table>
Algorithm

To calculate performance rates:

1) Find the patients who meet the initial patient population (i.e., the general group of patients that the performance measure is designed to address).

2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (i.e., the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.

3) From the patients within the denominator, find the patients who qualify for the Numerator (i.e., the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator.

4) From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception when exceptions have been specified (for this measure: medical reason(s) (e.g., above average risk patient, inadequate prep). If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.

If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure.

Calculation algorithm is included in attachment 2a1.30.

Copyright/Disclaimer

Physician Performance Measures (Measures) and related data specifications developed by the American Medical Association (AMA) in collaboration with the Physician Consortium for Performance Improvement (PCPI) and the National Committee for Quality Assurance (NCQA), pursuant to government sponsorship under Subcontract No. 6414-07-089 with Mathematica Policy Research under Contract HHSM-500-2005-000251(0004) with Centers for Medicare and Medicaid Services.

These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the AMA, (on behalf of the PCPI) or NCQA. Neither the AMA, NCQA, PCPI nor its members shall be responsible for any use of the Measures.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND. © 2008 American Medical Association and National Committee for Quality Assurance. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, NCQA, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications. CPT® contained in the Measures specifications is copyright 2007 American Medical Association. LOINC® copyright 2004 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004 College of American Pathologists (CAP). All Rights Reserved. Use of SNOMED CT® is only authorized within the United States.
<table>
<thead>
<tr>
<th><strong>Status</strong></th>
<th>Maintenance, Original Endorsement: Jan 17, 2011, Most Recent Endorsement: Jan 17, 2011</th>
</tr>
</thead>
</table>
| **Steward** | American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)  
Other organizations: American Society for Gastrointestinal Endoscopy (ASGE)/American Gastroenterological Association (AGA)/National Committee for Quality Assurance |
| **Description** | Percentage of patients aged 18 years and older receiving a surveillance colonoscopy, with a history of a prior colonic polyp in previous colonoscopy findings who had a follow-up interval of 3 or more years since their last colonoscopy documented in the colonoscopy report |
| **Type** | Process |
| **Data Source** | Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Imaging/Diagnostic Study, Electronic Clinical Data : Registry N/A |
| **Level** | Clinician : Group/Practice, Clinician : Individual, Clinician : Team |
| **Setting** | Ambulatory Care : Ambulatory Surgery Center (ASC), Ambulatory Care : Clinician Office/Clinic, Hospital/Acute Care Facility |
| **Numerator Statement** | Patients who had an interval of 3 or more years since their last colonoscopy |
| **Numerator Details** | Time Window: Every procedure within the denominator time window.  
Patients will be counted in the numerator if the current colonoscopy (in the denominator was performed at least 3 years after the date of the prior colonoscopy.  
In Stage 2, we will submit EHR specifications and claims specifications; the combination of the 2 specifications can be used in registry reporting. The data stream for registries can be claims, EHR or manual data entry.  
For EHR, patients will be counted based on looking back to determine if at least 3 years passed between the current and prior colonoscopies. The date of the prior colonoscopy will be searched in the EHR, and then compared to the date of the current colonoscopy (ie, colonoscopy performed during the measurement period). If the prior colonoscopy was performed at least 3 years prior to the current colonoscopy, then the patient will meet the measure.  
For claims data, a CPT Category II code will be reported to indicate that the interval between the current colonoscopy and the prior colonoscopy was at least 3 years. |
| **Denominator Statement** | All patients aged 18 years and older receiving a surveillance colonoscopy with a history of a prior colonic polyp in a previous colonoscopy |
| **Denominator Details** | Time Window: All patients aged 18 years and older receiving a surveillance colonoscopy with a history of a prior colonic polyp in a previous colonoscopy  
The denominator includes patients at least 18 years of age who have a history of colonic polyps who also received a colonoscopy during the measurement period. The denominator details will include the patient age criterion, applicable ICD-9-CM, ICD-10-CM, SNOMED-CT diagnosis codes for history of colonic polyps, and applicable CPT, G codes and SNOMED-CT codes for receiving a surveillance colonoscopy.  
In Stage 2, we will submit EHR specifications and claims specifications; the combination of the 2 specifications can be used in registry reporting. The data stream for registries can be claims, EHR or manual data entry. |
| Exclusions | Documentation of medical reason(s) for an interval of less than 3 years since the last colonoscopy (eg, last colonoscopy incomplete, last colonoscopy had inadequate prep, piecemeal removal of adenomas, or last colonoscopy found greater than 10 adenomas)  
OR  
Documentation of a system reason(s) for an interval of less than 3 years since the last colonoscopy (eg, unable to locate previous colonoscopy report, previous colonoscopy report was incomplete) |
|---|---|
| Exclusion Details | The PCPI exception methodology uses three categories of reasons for which a patient may be removed from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For this measure, exceptions may include medical reason(s) (eg, last colonoscopy incomplete, last colonoscopy had inadequate prep, piecemeal removal of adenomas, or last colonoscopy found greater than 10 adenomas) or system reason(s) for an interval of less than 3 years since the last colonoscopy (eg, unable to locate previous colonoscopy report, previous colonoscopy report was incomplete). Where examples of exceptions are included in the measure language, value sets for these examples are developed and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients’ medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician’s exceptions data to identify practice patterns and opportunities for quality improvement. Additional details by data source are as follows:  
For EHR:  
Patients will be excluded from the denominator if there is documentation of a medical or system reason for performing a colonoscopy within 3 years (less than 3 years) since the last colonoscopy  
• Examples of medical reasons include: the last colonoscopy was incomplete or had inadequate prep, there was piecemeal removal of adenomas, or the last colonoscopy found greater than 10 adenomas  
• Examples of system reasons include: unable to locate previous colonoscopy report, previous colonoscopy report was incomplete)  
Value sets for the examples included in the medical or system reasons will be developed to identify patients with allowable exceptions.  
For Claims:  
Patients will also be excluded from the denominator if there is documentation of a medical or system reason for recommending a subsequent colonoscopy within 3 years from the current colonoscopy. A CPT Category II code will be reported for patients who have an allowable exception to the measure. |
| Risk Adjustment | No risk adjustment or risk stratification  
N/A  
<p>| Stratification | We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected. Stratification by insurance coverage (Commercial, Medicare and Medicaid) is recommended by some implementers. |
| Type Score | Rate/proportion |
| Algorithm | See sample calculation algorithm attached |</p>
<table>
<thead>
<tr>
<th>Copyright/Disclaimer</th>
<th>Physician Performance Measures (Measures) and related data specifications developed by the American Medical Association (AMA) in collaboration with the Physician Consortium for Performance Improvement ® (PCPI) and the National Committee for Quality Assurance (NCQA), pursuant to government sponsorship under Subcontract No. 6414-07-089 with Mathematica Policy Research under Contract HHSM-500-2005-000251(0004) with Centers for Medicare and Medicaid Services. These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the AMA, (on behalf of the PCPI) or NCQA. Neither the AMA, NCQA, PCPI nor its members shall be responsible for any use of the Measures. THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND. © 2008 American Medical Association and National Committee for Quality Assurance. All Rights Reserved. Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, NCQA, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT ®) or other coding contained in the specifications. CPT ® contained in the Measures specifications is copyright 2007 American Medical Association. LOINC ® copyright 2004 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT ®) copyright 2004 College of American Pathologists (CAP). All Rights Reserved. Use of SNOMED CT ® is only authorized within the United States.</th>
</tr>
</thead>
</table>

| **C 2038 Performing vaginal apical suspension (uterosacral, iliococygeus, sacrospinous or sacral colpopexy) at the time of hysterectomy to address uterovaginal prolapse** |  |
| **Status** | New Submission |
| **Steward** | American Urogynecologic Society |
| **Description** | Percentage of female patients undergoing hysterectomy for the indication of uterovaginal prolapse in which a concomitant vaginal apical suspension (i.e. uterosacral, iliococygeus, sacrospinous or sacral colpopexy) is performed. |
| **Type** | Process |
| **Data Source** | Administrative claims, Paper Medical Records Practice Patterns Associated with Surgical Care of Pelvic Organ Prolapse: A Targeted Chart Review |
| **Level** | Clinician : Group/Practice, Clinician : Individual |
| **Setting** | Hospital/Acute Care Facility |
| **Numerator Statement** | The number of female patients who have a concomitant vaginal apical suspension (i.e. uterosacral, iliococygeus, sacrospinous or sacral colpopexy) at the time of hysterectomy for uterovaginal prolapse. |
| **Numerator Details** | Time Window: CPT codes for uterosacral, iliococygeus, sacrospinous or sacral colpopexy |
### C 2038 Performing vaginal apical suspension (uterosacral, iliococygeus, sacrospinous or sacral colpopexy) at the time of hysterectomy to address uterovaginal prolapse

<table>
<thead>
<tr>
<th><strong>Denominator Statement</strong></th>
<th>Hysterectomy, performed for the indication of uterovaginal prolapse</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Denominator Details</strong></td>
<td>Time Window:</td>
</tr>
<tr>
<td></td>
<td>Hysterectomy, performed for the indication of uterovaginal prolapse as identified the ICD-9 diagnosis codes for utero/vaginal prolapse and the CPT codes for hysterectomy.</td>
</tr>
</tbody>
</table>
| **Exclusions**            | • Patients with a gynecologic or other pelvic malignancy noted at the time of hysterectomy
|                           | • Patients undergoing a concurrent obliterate procedure (vaginectomy)
|                           | • Patients undergoing excision of prolapsed cervix only (prior sub-total hysterectomy) |
| **Exclusion Details**     | ICD-9 diagnosis codes for gynecologic cancers. CPT codes for vaginectomy. |
| **Risk Adjustment**       | No, we do not plan to risk adjust the measure. |
| **Stratification**        | No, we do not plan to stratify the measure results. |
| **Copyright/Disclaimer**  | None |

### C 2052 Reduction of Complications through the use of Cystoscopy during Surgery for Stress Urinary Incontinence

<table>
<thead>
<tr>
<th><strong>Status</strong></th>
<th>New Submission</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Steward</strong></td>
<td>American Urological Association Other organizations: American Congress of Obstetricians and Gynecologists (ACOG)</td>
</tr>
<tr>
<td><strong>Description</strong></td>
<td>Percentage of SUI surgeries for which cystoscopy was used during the surgical procedure to reduce complications</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Process</td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
<td>Administrative claims, Paper Medical Records</td>
</tr>
<tr>
<td><strong>Level</strong></td>
<td>Clinician : Individual</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Ambulatory Care : Clinician Office/Clinic</td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
<td>Female patients who had SUI surgery for which cystoscopy was used during the surgical procedure to reduce complications</td>
</tr>
<tr>
<td><strong>Numerator Details</strong></td>
<td>Time Window: The numerator will be calculated using CPT codes.</td>
</tr>
<tr>
<td><strong>Denominator Statement</strong></td>
<td>Female patients who had SUI surgeries (without concomitant surgery for prolapse)</td>
</tr>
<tr>
<td><strong>Denominator Details</strong></td>
<td>Time Window: The denominator will be calculated using CPT codes and patient characteristics, such as gender and age (adult patients). Concomitant prolapse surgery includes repair of cystocele, enterocoele, rectocele or vaginal vault prolapse or hysterectomy performed due to uterine prolapse.</td>
</tr>
</tbody>
</table>
C 2052 Reduction of Complications through the use of Cystoscopy during Surgery for Stress Urinary Incontinence

Exclusions
Documentation of medical reason(s) for not using cystoscopy during SUI surgery (patients for whom the use of a cystoscope may not be appropriate, such as the presence of a new cystostomy repair). The panel noted that endoscopy after a new repair should be cautiously used. Concomitant prolapse surgery is an exclusion.

Exclusion Details
Exclusions will be calculated using CPT codes and patient characteristics, such as gender and age.

Risk Adjustment
N/A

Stratification
N/A

Copyright/Disclaimer
© 2012 American Urological Association. All Rights Reserved. Physician Performance Measures (Measures) and related data specifications have been developed by the American Urological Association (AUA) and the American Congress of Obstetricians and Gynecologists (ACOG) These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. Neither AUA, ACOG, the American Medical Association (AMA), the AMA-convened Physician Consortium for Performance Improvement® (PCPI™) nor its members shall be responsible for any use of the Measures. AUA and ACOG encourage use of these Measures by other health care professionals, where appropriate.

C 2056 Colonoscopy Quality Index

Status
New Submission

Steward
Quality Quest for Health of Illinois

Description
This is a composite measure of the percentage of patients undergoing screening or surveillance colonoscopy who meet all individual quality elements (Appropriate indication for colonoscopy, standardized assessments of medical risk and bowel preparation, complete examination with photo documentation, free of serious complications, withdrawal time recorded, all essential polyp information recorded if polyp(s) identified, recommendation for follow-up colonoscopy consistent with patient history and examination findings), and the completion rate of each individual quality element.

Type
Process

Data Source
Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Laboratory, Other, Paper Medical Records, Electronic Clinical Data : Registry

Level
Facility, Clinician : Group/Practice, Clinician : Individual, Population : Regional

Setting
Ambulatory Care : Ambulatory Surgery Center (ASC), Hospital/Acute Care Facility

Numerator Statement

Numerator Details
Time Window:
1) Appropriate indication for colonoscopy:
### C2056 Colonoscopy Quality Index

**A) Appropriate indication for screening colonoscopy:**
- a1) Patient has no personal or family history of colorectal cancer or pre-cancerous polyp(s), has not had a colonoscopy in the past 10 years and is > 50 years; or
- a2) Patient has one or more first-degree relatives with pre-cancerous polyp(s) or one first-degree relative with colorectal cancer after age 60, has not had a colonoscopy in the past ten years and is > 40 years; or
- a3) Patient has a first degree relative with colorectal cancer before age 60 or 2 or more first degree relatives with colorectal cancer at any age, has not had a colonoscopy in the past five years and is > 40 years

*OR*

**B) Appropriate indication for surveillance colonoscopy:**
- b1) Patient with prior diagnosis of colorectal cancer, negative clearance colonoscopy at time of resection with colonoscopy not more often than year one, year four and every five years if normal or
- b2) Patient with low anterior resection for rectal cancer without pelvic radiation or mesorectal resection with flexible sigmoidoscopy not more often than every 3 months for up to 3 years in addition to colonoscopy not more often than year one, year four and every five years if normal; or
- b3) Patient with 1-2 small tubular adenoma(s) on most recent colonoscopy, has not had colonoscopy in the past 5 years; or
- b4) Patient with three to ten adenomas <1 cm on most recent colonoscopy, has not had colonoscopy in the past 3 years; or
- b5) Patient with advanced neoplasia (>1 cm adenoma, villous histology, high-grade dysplasia) or with up to ten adenomas on most recent colonoscopy, has not had colonoscopy in the past 3 years; or
- b6) Patient with greater than ten adenomas or with > one serrated polyp on most recent colonoscopy, has not had colonoscopy in past 12 months; or
- b7) Patient with sessile polyp > 1 cm with incomplete excision on most recent colonoscopy, has not had colonoscopy in past 2 months: or
- b8) Patient with history of pre-cancerous findings with negative most recent screening colonoscopy, has not had a colonoscopy in past 5 years

2. Standardized medical risk assessment: American Society of Anesthesiology Physical Status (class 1-5) recorded

3. Standardized assessment of bowel prep: Assessment as adequate to detect polyps > 5 mm (e.g., excellent, good or fair) or inadequate (e.g., poor or unsatisfactory) recorded. Please refer to Lieberman et al 2007.

4. Complete examination: Cecal intubation or anatomically complete colonoscopy was accomplished; (element null if bowel prep is deemed poor or unsatisfactory)

5. Cecal photo taken: Picture of the cecum; N/A is acceptable if examination is not complete.

6. All essential polyp information recorded: If polyps are removed, the number, size, location, morphology (if >4mm in size), method and completeness of removal all recorded

7. Withdrawal time was recorded: Withdrawal time from cecum to extubation recorded

8. Free of serious complications: Patient did not have bowel perforation, blood transfusion, cardiopulmonary arrest, hospitalization or death prior to discharge home
9. Appropriate follow-up recommendation: Follow up recommendation is consistent with patient history and examination findings per indication for screening colonoscopy.

Patient level data is collected on each screening or surveillance colonoscopy performed by the colonoscopy center, rules are applied (e.g., exclusion for poor bowel prep) by the data collection database provided by Quality Quest, and each quarter de-identified and encrypted patient-level data is electronically transferred to the registry on the Quality Quest data portal, and calculations are made on the most recent 12 months.

Please refer to the Definitions & Abbreviations document attached as supplemental materials for additional information such as bowel prep scoring.


<table>
<thead>
<tr>
<th>Denominator Statement</th>
<th>All adults undergoing screening or surveillance colonoscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denominator Details</td>
<td>Time Window: All adults undergoing screening or surveillance colonoscopy. Patient level data is collected on each screening or surveillance colonoscopy performed by the colonoscopy center, rules are applied (e.g., exclusion for poor bowel prep) by the data collection database provided by Quality Quest, and each quarter de-identified and encrypted patient-level data is electronically transferred to the registry on the Quality Quest data portal, and calculations are made on the most recent 12 months.</td>
</tr>
<tr>
<td>Exclusions</td>
<td>Patients with a personal or family history of familial adenomatous polyposis, hereditary non-polyposis colorectal cancer or inflammatory bowel disease are excluded from the denominator. Patients assessed as poor or unsatisfactory bowel preparation are excluded from the denominator.</td>
</tr>
<tr>
<td>Exclusion Details</td>
<td>Patients with a personal or family history of familial adenomatous polyposis, hereditary non-polyposis colorectal cancer or inflammatory bowel disease are excluded from the denominator. Patients assessed as poor or unsatisfactory bowel preparation are excluded from the denominator. Patient level data is collected on each screening or surveillance colonoscopy performed by the colonoscopy center, rules are applied (e.g., exclusion for poor bowel prep) by the data collection database provided by Quality Quest, and each quarter de-identified and encrypted patient-level data is electronically transferred to the registry on the Quality Quest data portal, and calculations are made on the most recent 12 months.</td>
</tr>
<tr>
<td>Risk Adjustment</td>
<td>N/A</td>
</tr>
<tr>
<td>Stratification</td>
<td>N/A</td>
</tr>
<tr>
<td>Copyright/Disclaimer</td>
<td>© Quality Quest for Health of Illinois, Inc., 2008. All rights reserved.</td>
</tr>
<tr>
<td><strong>C 2059 IBD preventive care: corticosteroid sparing therapy</strong></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td></td>
</tr>
<tr>
<td><strong>Status</strong></td>
<td>New Submission</td>
</tr>
<tr>
<td><strong>Steward</strong></td>
<td>American Gastroenterological Association Other organizations: This measure was developed via the Physician Consortium for Physician Improvement (PCPI(R))Independent Measures Development Process. In addition to a PCPI representative there were representatives from the Crohn’s and Colitis Foundation of America (CCFA) and American Society of Colon and Rectal Surgeons.</td>
</tr>
<tr>
<td><strong>Description</strong></td>
<td>Percentage of patients aged 18 years and older with a diagnosis of inflammatory bowel disease who have been managed by corticosteroid* greater than or equal to 10mg/day for 60 or greater consecutive days that have been prescribed corticosteroid sparing therapy in the last reporting year.</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Process</td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
<td>Electronic Clinical Data : Registry The AGA Digestive Health Recognition Program(TM)</td>
</tr>
<tr>
<td><strong>Level</strong></td>
<td>Clinician : Individual</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Ambulatory Care : Clinician Office/Clinic</td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
<td>Patients managed with corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days AND prescribed a corticosteroid sparing therapy (e.g. thiopurines, methotrexate, or anti-TNF agents).</td>
</tr>
<tr>
<td><strong>Numerator Details</strong></td>
<td>Time Window: CPT Category II codes have been assigned for purposes of PQRS. Subsequently the AGA Digestive Health Recognition Program (TM) has been launched. In this program an online data collection form to record clinical data for each patient will be submitted to a registry. Related definition: Prednisone equivalents can be determined using the following: 1 mg of prednisone = 1 mg of prednisolone; 5 mg of cortisone; 4 mg of hydrocortisone; 0.8 mg of triamcinolone; 0.8 mg of methylprednisolone; 0.15 mg of dexamethasone; 0.15 mg of betamethasone.</td>
</tr>
<tr>
<td><strong>Denominator Statement</strong></td>
<td>All patients aged 18 years and older with a diagnosis of inflammatory bowel disease.</td>
</tr>
<tr>
<td><strong>Denominator Details</strong></td>
<td>Time Window: For PQRS: Age and ICD9 /ICD10 codes in combination with CPT Service Codes. AGA Digestive Health Recognition Program (TM): Uses an online data collection form to record age and diagnosis data for each patient (in sample) will be submitted to a registry. In the AGA Digestive Health Recognition Program (TM) because of the use of clinical data those that have not received a dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days are excluded from the denominator.</td>
</tr>
<tr>
<td><strong>Exclusions</strong></td>
<td>PQRS: Documentation of medical reason(s) for not treating with corticosteroid sparing therapy (e.g., toxicity, allergy, loss of effectiveness). In the AGA Digestive Health Recognition Program (TM) because of the use of clinical data those that have not received a dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days are excluded from the denominator. We have also been able to include a patient exclusion for example if the patient refuses steroid sparing therapy.</td>
</tr>
<tr>
<td><strong>Exclusion Details</strong></td>
<td>PQRS: Add a P1 modifier to the CPT Category II code that identifies that corticosteroid sparing therapy prescribed. AGA Digestive Health Recognition Program: Addressed with specific questions in the data collection form regarding these exclusions.</td>
</tr>
</tbody>
</table>
### C 2059 IBD preventive care: corticosteroid sparing therapy

<table>
<thead>
<tr>
<th>Risk Adjustment</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stratification</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Copyright/Disclaimer**

© 2010-2011 American Gastroenterological Association. All Rights Reserved. Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AGA, AMA the PCPI and its members disclaim all liability for use or accuracy of any current procedural terminology (CPT®) or other coding contained in the specifications. CPT® contained in the Measure specifications is copyright 2004- 2010 American Medical Association.

LOINC® is copyright 2004-2010 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms® (SNOMED CT®) copyright 2004-2010 International Health Terminology Standards Development Organisation. All Rights Reserved. Physician performance measures (measures) and related data specifications have been developed by the American Gastroenterological Association (AGA) Institute. These performance measures are not clinical guidelines and do not establish a standard of medical care, nor have been tested for all potential applications. Neither the AGA, the American Medical Association (AMA), the Physician Consortium for Performance Improvement® (PCPI™), nor its members shall be responsible for any use of the measures.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

### C 2063 Use of cystoscopy concurrent with prolapse repair surgery

<table>
<thead>
<tr>
<th>Status</th>
<th>New Submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steward</td>
<td>American Urogynecologic Society</td>
</tr>
<tr>
<td>Description</td>
<td>Percentage of patients that undergo concurrent cystoscopy at the time of surgery for correction of anterior and/or apical vaginal prolapse to check for lower urinary tract injury.</td>
</tr>
<tr>
<td>Type</td>
<td>Process</td>
</tr>
<tr>
<td>Data Source</td>
<td>Administrative claims, Paper Medical Records Practice Patterns Associated with Surgical Care of Pelvic Organ Prolapse: A Targeted Chart Review</td>
</tr>
<tr>
<td>Level</td>
<td>Clinician : Group/Practice, Clinician : Individual</td>
</tr>
<tr>
<td>Setting</td>
<td>Hospital/Acute Care Facility</td>
</tr>
<tr>
<td>Numerator Statement</td>
<td>Numerator is the number of female patients where a concurrent intraoperative cystoscopy was performed at the time of surgery for correction of anterior and/or apical vaginal prolapse to check for lower urinary tract injury.</td>
</tr>
<tr>
<td>Numerator Details</td>
<td>Time Window: Numerator is measured by all women undergoing any vaginal prolapse repair where a concurrent intraoperative cystoscopy was perform. The cystoscopy will be identified by CPT code(s). Any vaginal prolapse repair will be located int he patient’s record using CPT codes for anterior and/or apical vaginal prolapse surgeries.</td>
</tr>
<tr>
<td>Denominator Statement</td>
<td>Denominator is the number of female patients undergoing any prolapse repair surgery for correction of anterior and/or apical vaginal prolapse.</td>
</tr>
</tbody>
</table>
### C 2063 Use of cystoscopy concurrent with prolapse repair surgery

<table>
<thead>
<tr>
<th><strong>Denominator</strong></th>
<th><strong>Details</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Time Window:</strong></td>
<td>Denominator is identified as the number of female patients undergoing any prolapse repair surgery for correction of anterior and/or apical vaginal prolapse and these female patients will be identified by using CPT codes for these procedures.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Exclusions</strong></th>
<th><strong>Details</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>There are no exclusions from the target population.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Exclusion</strong></th>
<th><strong>Details</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>There are no exclusions from the target population.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Risk Adjustment</strong></th>
<th><strong>Details</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>We are not planning to risk adjust this measure.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Stratification</strong></th>
<th><strong>Details</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>We do not plan to stratify the results.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Copyright/Disclaimer</strong></th>
<th><strong>Details</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

### C 2065 Gastrointestinal Hemorrhage Mortality Rate (IQI #18)

<table>
<thead>
<tr>
<th><strong>Status</strong></th>
<th>New Submission</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>Steward</strong></th>
<th>Agency for Healthcare Research and Quality Other organizations: Battelle Memorial Institute, Stanford University and the University of California-Davis</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>Description</strong></th>
<th>Percent of discharges with an in-hospital death among cases with a principal diagnosis of gastrointestinal hemorrhage</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>Type</strong></th>
<th>Outcome</th>
</tr>
</thead>
</table>

|-----------------|----------------------------------------------------------|

<table>
<thead>
<tr>
<th><strong>Level</strong></th>
<th>Facility</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>Setting</strong></th>
<th>Hospital/Acute Care Facility</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>Numerator</strong></th>
<th><strong>Statement</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of in-hospital deaths among cases meeting the inclusion and exclusion rules for the denominator</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Numerator</strong></th>
<th><strong>Details</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Time Window:</strong></td>
<td>All discharges with a Disposition of Patient (DISP) coded as &quot;died&quot; (20)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Denominator</strong></th>
<th><strong>Statement</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All discharges, age 18 years and older, with a principal diagnosis code of gastrointestinal hemorrhage</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Denominator</strong></th>
<th><strong>Details</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Time Window:</strong></td>
<td>ICD-9-CM principal diagnosis code of Gastrointestinal hemorrhage (see below for detail) Time window may be determined by the user, but is generally a calendar year. ICD-9-CM Gastrointestinal hemorrhage diagnosis codes: 4560 ESOPHAG VARICES W BLEED 5307 MALLORY-WEISS SYNDROME 53021 ULCER ESOPHAGUS W BLEED</td>
</tr>
</tbody>
</table>

**ICD-9-CM Gastrointestinal hemorrhage diagnosis codes:**
- 4560 ESOPHAG VARICES W BLEED
- 5307 MALLORY-WEISS SYNDROME
- 53021 ULCER ESOPHAGUS W BLEED
<table>
<thead>
<tr>
<th>C 2065 Gastrointestinal Hemorrhage Mortality Rate (IQI #18)</th>
</tr>
</thead>
<tbody>
<tr>
<td>53082 ESOPHALGEAL HEMORRHAGE</td>
</tr>
<tr>
<td>53100 AC STOMACH ULCER W HEM</td>
</tr>
<tr>
<td>53101 AC STOMAC ULC W HEM-OBST</td>
</tr>
<tr>
<td>53120 AC STOMAC ULC W HEM-PERF</td>
</tr>
<tr>
<td>53121 AC STOM ULC HEM/PERF- OBS</td>
</tr>
<tr>
<td>53140 CHR STOMACH ULC W HEM</td>
</tr>
<tr>
<td>53141 CHR STOM ULC W HEM-OBSTR</td>
</tr>
<tr>
<td>53160 CHR STOMACH ULC HEM/PERF</td>
</tr>
<tr>
<td>53161 CHR STOM ULC HEM/PERF-OB</td>
</tr>
<tr>
<td>53200 AC DUODENAL ULCER W HEM</td>
</tr>
<tr>
<td>53201 AC DUODEN ULC W HEM-OBST</td>
</tr>
<tr>
<td>53220 AC DUODEN ULC W HEM-PERF</td>
</tr>
<tr>
<td>53221 AC DUOD ULC HEM/PERF- OBS</td>
</tr>
<tr>
<td>53240 CHR DUODEN ULCER W HEM</td>
</tr>
<tr>
<td>53260 CHR DUODEN ULC W HEM/PERF</td>
</tr>
<tr>
<td>53261 CHR DUOD ULC W HEM-PERF-OB</td>
</tr>
<tr>
<td>53300 AC PEPTIC ULCER W HEMORR</td>
</tr>
<tr>
<td>53301 AC PEPTIC ULC W HEM-OBST</td>
</tr>
<tr>
<td>53320 AC PEPTIC ULC W HEM-PERF</td>
</tr>
<tr>
<td>53321 AC PEPT ULC HEM/PERF- OBS</td>
</tr>
<tr>
<td>53340 CHR PEPTIC ULCER W HEM</td>
</tr>
<tr>
<td>53341 CHR PEPTIC ULC W HEM-_OBS</td>
</tr>
<tr>
<td>53360 CHR PEPT ULC W HEM-PERF</td>
</tr>
<tr>
<td>53361 CHR PEPT ULC HEM/PERF-OB</td>
</tr>
<tr>
<td>53400 AC MARGINAL ULCER W HEM</td>
</tr>
<tr>
<td>53401 AC MARGIN ULC W HEM-OBST</td>
</tr>
<tr>
<td>53420 AC MARGIN ULC W HEM-PERF</td>
</tr>
<tr>
<td>53421 AC MARG ULC HEM/PERF- OBS</td>
</tr>
<tr>
<td>53440 CHR MARGINAL ULCER W HEM</td>
</tr>
<tr>
<td>53441 CHR MARGIN ULC W HEM-OBS</td>
</tr>
<tr>
<td>53460 CHR MARGIN ULC HEM/PERF</td>
</tr>
<tr>
<td>53461 CHR MARG ULC HEM/PERF- OBS</td>
</tr>
<tr>
<td>53501 ACUTE GASTRITIS W HMRHG</td>
</tr>
<tr>
<td>53511 ATRPH GASTRITIS W HMRHG</td>
</tr>
<tr>
<td>53521 GSTR MCSL HYPRT W HMRG</td>
</tr>
<tr>
<td>53531 ALCHL GSTRITIS W HMRHG</td>
</tr>
<tr>
<td>53541 OTH SPF GASTRT W HMRHG</td>
</tr>
<tr>
<td>53551 GSTR/DDNTS NOS W HMRHG</td>
</tr>
<tr>
<td>53561 DUODENITIS W HMRHG</td>
</tr>
<tr>
<td>53783 ANGIO STM/DUDN W HMRHG</td>
</tr>
<tr>
<td>53784 DIEULAFYO LE,STOM&amp;DUOD</td>
</tr>
<tr>
<td>56202 DVRTCL SML INT W HMRHG</td>
</tr>
<tr>
<td>56203 DVRTCLI SML INT W HMRHG</td>
</tr>
<tr>
<td>C 2065 Gastrointestinal Hemorrhage Mortality Rate (IQI #18)</td>
</tr>
<tr>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>56212 DVRTCLO COLON W HMRHG</td>
</tr>
<tr>
<td>56213 DVRTCLI COLON W HMRHG</td>
</tr>
<tr>
<td>5693 RECTAL &amp; ANAL HEMORRHAGE</td>
</tr>
<tr>
<td>56985 ANGIO INTES W HMRHG</td>
</tr>
<tr>
<td>56986 DIEULAFoy LES, INTESTINE</td>
</tr>
<tr>
<td>5780 HEMATEMESIS</td>
</tr>
<tr>
<td>5781 BLOOD IN STOOL</td>
</tr>
<tr>
<td>5789 GASTROINTEST HEMORR NOS</td>
</tr>
</tbody>
</table>

**Exclusions**

Exclude cases:
- transferring to another short-term hospital
- MDC 14 (pregnancy, childbirth, and puerperium)
- with missing discharge disposition, gender, age, quarter, year or principal diagnosis

**Exclusion Details**

- transferring to another short-term hospital (Disposition of Patient (DISP) coded as Transfer to Short-term Hospital (2))
- Major Diagnostic Category 14 (pregnancy, childbirth, and puerperium) - note that this exclusion is implied by the fact that the denominator is limited to patients with a principal diagnosis code for gastrointestinal hemorrhage, which maps to MDC 6 (digestive)
- missing discharge disposition (DISP=missing)
- missing gender (SEX=missing)
- missing age (AGE=missing)
- missing quarter (DQTR=missing)
- missing year (YEAR=missing)
- missing principal diagnosis (DX1=missing)
### C 2065 Gastrointestinal Hemorrhage Mortality Rate (IQI #18)

**Risk Adjustment**

The predicted value for each case is computed using a two-stage hierarchical model (the first stage is a logistic regression using Generalized Estimating Equations (GEE) to account for clustering of patients within hospitals; the second stage is a reliability weight). The covariates in the logistic regression include age (in 5-year age groups pooled), APR-DRG and APR-DRG Risk of Mortality subclass, MDC and transfer-in status. The reference population used in the regression is the universe of discharges for states that participate in the HCUP State Inpatient Data (SID) for the years 2008, a database consisting of 42 states and approximately 30 million adult discharges.

<table>
<thead>
<tr>
<th>INTERCEPT</th>
<th>AGE 18 to 59</th>
<th>AGE 65+</th>
</tr>
</thead>
<tbody>
<tr>
<td>APR-DRG '2201' (e.g., APR-DRG 220, Risk of Mortality level 1)</td>
<td>APR-DRG '2202' (e.g., APR-DRG 220, Risk of Mortality level 2)</td>
<td>APR-DRG '2203' (e.g., APR-DRG 220, Risk of Mortality level 3)</td>
</tr>
<tr>
<td>APR-DRG '2204' (e.g., APR-DRG 220, Risk of Mortality level 4)</td>
<td>APR-DRG '2211'</td>
<td>APR-DRG '2212'</td>
</tr>
<tr>
<td>APR-DRG '2213'</td>
<td>APR-DRG '2214'</td>
<td>APR-DRG '2411' to '2413'</td>
</tr>
<tr>
<td>APR-DRG '2414'</td>
<td>APR-DRG '2421' to '2423'</td>
<td>APR-DRG '2424'</td>
</tr>
<tr>
<td>APR-DRG '2441' to '2442'</td>
<td>APR-DRG '2443'</td>
<td>APR-DRG '2444'</td>
</tr>
<tr>
<td>APR-DRG '2532'</td>
<td>APR-DRG '2533'</td>
<td>APR-DRG '2534'</td>
</tr>
<tr>
<td>APR-DRG '2541' to '2534'</td>
<td>APR-DRG '2544'</td>
<td>MDC Other</td>
</tr>
</tbody>
</table>

**Transfer-in**  
Detailed risk model available at [http://www.qualityindicators.ahrq.gov/Downloads/Modules/IQI/V44/Risk%20Adjustment%20Tables%20IQI%204.4.pdf](http://www.qualityindicators.ahrq.gov/Downloads/Modules/IQI/V44/Risk%20Adjustment%20Tables%20IQI%204.4.pdf)


**Stratification** Not applicable

**Copyright/Disclaimer** Not applicable
Appendix B: Project Steering Committee and NQF Staff

STEERING COMMITTEE

Andrew Baskin, MD (Co-Chair)
Aetna, Blue Bell, PA

Christopher Saigal, MD, MPH (Co-Chair)
UCLA Medical Center, Los Angeles, CA

Liliana Bordeianou, MD, MPH
Massachusetts General Hospital, Cambridge, MA

Zahid Butt, MD
Medisolv Inc., Columbia, MD

Robert Ellis
Consumers' Checkbook, Ashburn, VA

Nancy Faller, RN, MSN, PhD, CWOCN, WOCN
Turners Falls, MA

Edward Gill, MD
VCU Medical Center, Richmond, VA

Johannes Koch, MD
Virginia Mason Medical Center, Seattle WA

Jenifer Lightdale, MD, MPH
Boston Children’s Hospital, Boston, MA

Richard Luetkemeyer, MD
HealthStrategy LLC, Peoria, IL

Alayne Markland, DO, MSc
University of Alabama at Birmingham, Birmingham, AL

Paul Merguerian, MS, MD
Seattle Children’s Hospital, Seattle, WA

John Morton, MD, MPH, FACS
Stanford University, Stanford, CA

Anne Pelletier-Cameron, MD
University of Michigan, Ann Arbor, MI

W. Stuart Reynolds, MD, MPH
Vanderbilt University Medical Center, Nashville, TN
Philip Schoenfeld, MD
VA Ann Arbor Healthcare System, Ann Arbor, MI

Judith Tobin, PT, MBA
Centers for Medicare and Medicaid Services, Washington, DC

NQF STAFF

Helen Burstin, MD, MPH
Senior Vice President
Performance Measures

Heidi Bossley, MSN, MBA
Vice President
Performance Measures

Taroon Amin, MA, MPH
Senior Director
Performance Measures

Ashlie Wilbon, RN, MPH
Senior Project Manager
Performance Measures

Evan M. Williamson, MPH, MS
Project Analyst
Performance Measures
## Appendix C: Measures Endorsed in GI/GU since March 1, 2007

### GU Measures

<table>
<thead>
<tr>
<th>NQF Number</th>
<th>Title</th>
<th>Steward</th>
</tr>
</thead>
<tbody>
<tr>
<td>0030</td>
<td>Urinary Incontinence Management in Older Adults - a. Discussing urinary incontinence, b. Receiving urinary incontinence treatment – A patient reported measure</td>
<td>National Committee for Quality Assurance</td>
</tr>
<tr>
<td>0098</td>
<td>Urinary Incontinence: Assessment, Characterization, and Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older – an administrative measure</td>
<td>National Committee for Quality Assurance</td>
</tr>
<tr>
<td>0099 (Combined with #0098)</td>
<td>Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older</td>
<td>National Committee for Quality Assurance</td>
</tr>
<tr>
<td>0100 (Combined with #0098)</td>
<td>Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older</td>
<td>National Committee for Quality Assurance</td>
</tr>
<tr>
<td>0684</td>
<td>Percent of Residents with a Urinary Tract Infection (Long-Stay)</td>
<td>Centers for Medicare and Medicaid Services</td>
</tr>
<tr>
<td>0685</td>
<td>Percent of Low Risk Residents Who Lose Control of Their Bowels or Bladder (Long-Stay)</td>
<td>Centers for Medicare and Medicaid Services</td>
</tr>
<tr>
<td>0686</td>
<td>Percent of Residents Who Have/Had a Catheter Inserted and Left in Their Bladder (Long-Stay)</td>
<td>Centers for Medicare and Medicaid Services</td>
</tr>
<tr>
<td>NQF Number</td>
<td>Title</td>
<td>Steward</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0034</td>
<td>Colorectal Cancer Screening</td>
<td>National Committee for Quality Assurance</td>
</tr>
<tr>
<td>0223</td>
<td>Adjuvant chemotherapy is considered or administered within 4 months (120 days) of surgery to patients under the age of 80 with AJCC III (lymph node positive) colon cancer</td>
<td>American College of Surgeons</td>
</tr>
<tr>
<td>0225</td>
<td>At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer</td>
<td>American College of Surgeons</td>
</tr>
<tr>
<td>0392</td>
<td>Colorectal Cancer Resection Pathology Reporting- pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade</td>
<td>American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)</td>
</tr>
<tr>
<td>0460</td>
<td>Risk-Adjusted Morbidity and Mortality for Esophagectomy for Cancer</td>
<td>The Society of Thoracic Surgeons</td>
</tr>
<tr>
<td>0572</td>
<td>Follow-up after initial diagnosis and treatment of colorectal cancer: colonoscopy</td>
<td>Health Benchmarks-IMS Health</td>
</tr>
<tr>
<td>0622</td>
<td>GERD - Upper Gastrointestinal Study in Adults with Alarm Symptoms</td>
<td>ActiveHealth Management</td>
</tr>
<tr>
<td>0635</td>
<td>Chronic Liver Disease - Hepatitis A Vaccination</td>
<td>ActiveHealth Management</td>
</tr>
<tr>
<td>0658 <em>(Time Limited)</em></td>
<td>Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients</td>
<td>American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)</td>
</tr>
<tr>
<td>0659 <em>(Time Limited)</em></td>
<td>Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps- Avoidance of Inappropriate Use</td>
<td>American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)</td>
</tr>
<tr>
<td>0727</td>
<td>Gastroenteritis Admission Rate (pediatric)</td>
<td>Agency for Healthcare Research and Quality</td>
</tr>
<tr>
<td>1617</td>
<td>Patients Treated with an Opioid who are Given a Bowel Regimen</td>
<td>RAND Corporation</td>
</tr>
<tr>
<td>1854</td>
<td>Barrett’s Esophagus</td>
<td>College of American Pathologists</td>
</tr>
</tbody>
</table>
### Appendix D: Related Concepts & Measures

#### Comparison of NQF #0635 and NQF #0399

<table>
<thead>
<tr>
<th>NQF #0635 Chronic Liver Disease - Hepatitis A Vaccination</th>
<th>0399 Paired Measure: Hepatitis C: Hepatitis A Vaccination (paired with 0400)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Steward</strong></td>
<td>American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)</td>
</tr>
<tr>
<td><strong>Description</strong></td>
<td>Percentage of patients aged 18 years and older with a diagnosis of hepatitis C who have received at least one injection of hepatitis A vaccine, or who have documented immunity to hepatitis A</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Process</td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
<td>Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Laboratory, Patient Reported Data/Survey, Electronic Clinical Data : Pharmacy Claims ingested via ActiveHealth Management's rules engine, CareEngine. Electronic clinical data source for pharmacy, lab, and EHR data is ActiveCareTeam (clinical workflow tool and dashboard) and MyActiveHealth (PHR). Healthcare provider survey and patient survey included as a part of clinical alerts (aka Care Considerations) feedback section.</td>
</tr>
<tr>
<td><strong>Level</strong></td>
<td>Clinician : Group/Practice, Clinician : Individual, Clinician : Team</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Ambulatory Care : Clinician Office/Clinic, Other, Ambulatory Care : Urgent Care Hospital Outpatient Clinic</td>
</tr>
</tbody>
</table>

**0635 Chronic Liver Disease - Hepatitis A Vaccination**

**Steward**: ActiveHealth Management

**Description**: The percentage of adult patients with chronic liver disease who have received a hepatitis A vaccine

**Type**: Process

**Data Source**: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Healthcare Provider Survey, Electronic Clinical Data : Laboratory, Patient Reported Data/Survey, Electronic Clinical Data : Pharmacy Claims ingested via ActiveHealth Management's rules engine, CareEngine. Electronic clinical data source for pharmacy, lab, and EHR data is ActiveCareTeam (clinical workflow tool and dashboard) and MyActiveHealth (PHR). Healthcare provider survey and patient survey included as a part of clinical alerts (aka Care Considerations) feedback section.

**Level**: Population : National, Population : Regional

**Setting**: Ambulatory Care : Clinician Office/Clinic, Home Health
| 0635 Chronic Liver Disease - Hepatitis A Vaccination | 0399 Paired Measure: Hepatitis C: Hepatitis A Vaccination (paired with 0400)  
(Under review in the Infection Disease Project, 2012) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Numerator Statement</strong></td>
<td>Patients with chronic liver disease who have received a hepatitis A vaccine or who have been tested for immunity in the past. Keeping in consideration that providers who test for Hepatitis A immunity most likely intend to take action on the test results and that hepatitis A testing is usually communicated in the form of LOINC codes which do not indicate immunity confirmed, immunity testing is considered sufficient for completion of the numerator for this measure.</td>
</tr>
</tbody>
</table>
| **Numerator Details** | **Time Window:** Anytime in the past  
One of the following:  
1. At least 1 fill of Hepatitis A vaccine from claims or HIE anytime in the past  
2. At least 1 Hepatitis A vaccine procedure from claims or HIE anytime in the past  
3. At least 1 Hepatitis A antibody procedure from claims or HIE anytime in the past  
4. At least 1 Hepatitis A Lab result from claims or HIE anytime in the past  
5. Patient-reported data indicating that they received a Hepatitis A vaccine anytime in the past. | **Time Window:** Once during the measurement period  
Definition: *Received includes documentation that a patient received at least one injection of hepatitis A vaccine from another provider.  
EHR Specifications:  
eMeasure developed – see attached  
Claims Specifications:  
CPT Category II code (in development): 4148F – Hepatitis A vaccine injection administered or previously received  
OR  
CPT Category II code: 3215F – Patient has documented immunity to Hepatitis A. |
| **Denominator Statement** | All patients, ages 18 and older, diagnosed with chronic liver disease | All patients aged 18 years and older with a diagnosis of hepatitis C. |
| **Denominator Details** | **Time Window:** 12 months  
All of the following:  
1. Age >/= 18 years  
2. One of the following  
a. One of the following  
i. At least 2 diagnosis codes from claims or 1 diagnosis code from HIE for Chronic Hepatitis B in the past 24 months. | **Time Window:** 12 consecutive months  
EHR Specifications:  
eMeasure developed – see attached  
Claims Specifications:  
ICD-9-CM diagnosis codes: 070.51, 070.54, 070.70  
AND  
CPT Codes: 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, 99245 |
<table>
<thead>
<tr>
<th>0635 Chronic Liver Disease - Hepatitis A Vaccination</th>
<th>0399 Paired Measure: Hepatitis C: Hepatitis A Vaccination (paired with 0400)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ii. Patient self-reported data, via PHR or telephonic nurse assessment in our disease management program, confirming a diagnosis of Chronic Hepatitis B anytime in the past</td>
<td>(Under review in the Infection Disease Project, 2012)</td>
</tr>
<tr>
<td>iii. At least 2 hepatitis B surface or E antigen or DNA Labs Result Value &gt; 1 in the past 12 months from claims</td>
<td></td>
</tr>
<tr>
<td>iv. At least 2 diagnosis codes from claims for Chronic Hepatitis B anytime in the past with one of the following</td>
<td></td>
</tr>
<tr>
<td>A. At least 1 current fill of a Hepatitis B medication from HIE</td>
<td></td>
</tr>
<tr>
<td>b. One of the following</td>
<td></td>
</tr>
<tr>
<td>i. At least 2 diagnosis codes from claims or 1 diagnosis code from HIE for Chronic Hepatitis C in the past 24 months</td>
<td></td>
</tr>
<tr>
<td>ii. Patient self-reported data, via PHR or telephonic nurse assessment in our disease management program, confirming a diagnosis of Chronic Hepatitis C anytime in the past</td>
<td></td>
</tr>
<tr>
<td>iii. At least 1 hepatitis C antibody or RNA Labs Result Value &gt; 1 in the past 12 months</td>
<td></td>
</tr>
<tr>
<td>iv. Patient self-reported data, via PHR or telephonic nurse assessment in our disease management program, confirming a diagnosis of Chronic Hepatitis C anytime in the past</td>
<td></td>
</tr>
<tr>
<td>v. At least 2 diagnosis codes from claims for Chronic Hepatitis C anytime in the past with one of the following</td>
<td></td>
</tr>
<tr>
<td>A. At least 2 fills of a Hepatitis C medication from HIE</td>
<td></td>
</tr>
<tr>
<td>B. At least 2 fills of a Hepatitis C medication from claims in the past 24 months</td>
<td></td>
</tr>
<tr>
<td>C. At least 2 procedure codes for Hepatitis C treatment in the past 24 months from claims</td>
<td></td>
</tr>
<tr>
<td>D. At least 2 diagnosis codes from claims for chronic liver disease (excluding Hepatitis A) in the past 12 months</td>
<td></td>
</tr>
<tr>
<td><strong>0635 Chronic Liver Disease - Hepatitis A Vaccination</strong></td>
<td><strong>0399 Paired Measure: Hepatitis C: Hepatitis A Vaccination (paired with 0400)</strong> (Under review in the Infection Disease Project, 2012)</td>
</tr>
<tr>
<td>------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Exclusions</strong></td>
<td>Documentation of medical reason(s) for not receiving at least one injection of hepatitis A vaccine</td>
</tr>
<tr>
<td>Patients with a previous history of viral hepatitis A. General exclusions: 1. Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months; 2. Patients who have been in a skilled nursing facility in the last 3 months (this exclusion is included to avoid holding physicians who care for patients during a transitional period, e.g. temporary SNF placement, for their ongoing care; hence, the time limitation of 3 months).</td>
<td>Documentation of patient reason(s) for not receiving at least one injection of hepatitis A vaccine</td>
</tr>
</tbody>
</table>
| Exclusion Details          | The PCPI exception methodology uses three categories of reasons for which a patient may be removed from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For this measure, exceptions may include medical reason(s) or patient reason(s) for not receiving at least one injection of hepatitis A vaccine. Where examples of exceptions are included in the measure language, value sets for these examples are developed and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients’ medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician’s exceptions data to identify practice patterns and opportunities for quality improvement. Additional details by data source are as follows:
EHR Specifications:
eMeasure developed – see attached
Claims Specifications:
Report one of the following CPT Category II codes:
4148F-1P: Documentation of medical reason(s) for not administering at least one injection of hepatitis A vaccine
4148F-2P: Documentation of patient reason(s) for not administering at least one injection of hepatitis A vaccine |
| Risk Adjustment           | No risk adjustment or risk stratification
No risk adjustment necessary | No risk adjustment or risk stratification
None |
<p>| Stratification            | None | We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected. |</p>
<table>
<thead>
<tr>
<th>Type Score</th>
<th>Rate/proportion  better quality = higher score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Algorithm</td>
<td>To calculate performance rates:</td>
</tr>
<tr>
<td></td>
<td>1) Find the patients who meet the initial patient population (ie, the general group of patients that a set of performance measures is designed to address).</td>
</tr>
<tr>
<td></td>
<td>2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.</td>
</tr>
<tr>
<td></td>
<td>3) From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator.</td>
</tr>
<tr>
<td></td>
<td>4) From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator when exceptions have been specified [for this measure: medical reason(s) or patient reason(s)]. If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. --Although the exception cases are removed from the denominator population for the performance calculation, the exception rate (ie, percentage with valid exceptions) should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.</td>
</tr>
<tr>
<td></td>
<td>If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure. Calculation algorithm is included in e-measure which was emailed to NQF staff.</td>
</tr>
<tr>
<td>Submission items</td>
<td>0635 Chronic Liver Disease - Hepatitis A Vaccination</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>5.1 Identified measures:</td>
<td>0399 : Paired Measure: Hepatitis C: Hepatitis A Vaccination (paired with 0400)</td>
</tr>
<tr>
<td>5a.1 Are specs completely harmonized?</td>
<td>No</td>
</tr>
<tr>
<td>5a.2 If not completely harmonized, identify difference, rationale, impact:</td>
<td>While our measure includes adults with chronic liver disease in the denominator, measure 0399 includes only those with hepatitis C.</td>
</tr>
<tr>
<td>5b.1 If competing, why superior or rationale for additive value:</td>
<td>While our measure includes adults with chronic liver disease in the denominator, measure 0399 includes only those with hepatitis C. We feel that our measure is more encompassing of and brings attention to all of those individuals who should receive a hepatitis A vaccine. We have not yet discussed with the developers of measure 0399 to see if the endorsed measures can be combined and expanded.</td>
</tr>
</tbody>
</table>

**5b.1 If competing, why superior or rationale for additive value:**
# Comparison of NQF #0658 and NQF #0659

<table>
<thead>
<tr>
<th>Steward</th>
<th>American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)</th>
<th>American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Description</strong></td>
<td>Percentage of patients aged 50 years and older receiving a screening colonoscopy without biopsy or polypectomy who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report.</td>
<td>Percentage of patients aged 18 years and older receiving a surveillance colonoscopy, with a history of a prior colonic polyp in previous colonoscopy findings who had a follow-up interval of 3 or more years since their last colonoscopy documented in the colonoscopy report.</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Process</td>
<td>Process</td>
</tr>
<tr>
<td><strong>Level</strong></td>
<td>Clinician : Group/Practice, Clinician : Individual, Clinician : Team</td>
<td>Clinician : Group/Practice, Clinician : Individual, Clinician : Team</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Ambulatory Care : Ambulatory Surgery Center (ASC), Ambulatory Care : Clinician Office/Clinic</td>
<td>Ambulatory Care : Ambulatory Surgery Center (ASC), Ambulatory Care : Clinician Office/Clinic, Hospital/Acute Care Facility</td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
<td>Patients who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report</td>
<td>Patients who had an interval of 3 or more years since their last colonoscopy</td>
</tr>
</tbody>
</table>
| Numerator Details | Time Window: Once for each screening colonoscopy performed during the measurement period | Time Window: Every procedure within the denominator time window.  
Patients will be counted in the numerator if the current colonoscopy (in the denominator was performed at least 3 years after the date of the prior colonoscopy.  
In Stage 2, we will submit EHR specifications and claims specifications; the combination of the 2 specifications can be used in registry reporting. The data stream for registries can be claims, EHR or manual data entry.  
For EHR, patients will be counted based on looking back to determine if at least 3 years passed between the current and prior colonoscopies. The date of the prior colonoscopy will be searched in the EHR, and then compared to the date of the current colonoscopy (ie, colonoscopy performed during the measurement period). If the prior colonoscopy was performed at least 3 years prior to the current colonoscopy, then the patient will meet the measure.  
For claims data, a CPT Category II code will be reported to indicate that the interval between the current colonoscopy and the prior colonoscopy was at least 3 years. |
<p>| Denominator Statement | All patients aged 50 years and older receiving screening colonoscopy without biopsy or polypectomy | All patients aged 18 years and older receiving a surveillance colonoscopy with a history of a prior colonic polyp in a previous colonoscopy |</p>
<table>
<thead>
<tr>
<th>Measure Code</th>
<th>Measure Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0658</td>
<td>Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients</td>
</tr>
<tr>
<td>0659</td>
<td>Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use</td>
</tr>
</tbody>
</table>

### Denominator Details

**Denominator** Time Window: Each procedure/diagnostic study performed during 12 consecutive months

The denominator of this measure includes patients at least 50 years of age who receive a screening colonoscopy during the measurement period. The denominator details will include the patient age criterion and applicable CPT, G-Codes and SNOMED-CT procedure codes for a screening colonoscopy. The procedures that will be identified include only those without biopsy or polypectomy, meaning the patient did not have any polyps removed or biopsied during the colonoscopy procedure.

In Stage 2 of this pilot, we will submit EHR specifications and claims specifications.

**Denominator** Time Window: All patients aged 18 years and older receiving a surveillance colonoscopy with a history of a prior colonic polyp in a previous colonoscopy

The denominator includes patients at least 18 years of age who have a history of colonic polyps who also received a colonoscopy during the measurement period. The denominator details will include the patient age criterion, applicable ICD-9-CM, ICD-10-CM, SNOMED-CT diagnosis codes for history of colonic polyps, and applicable CPT, G codes and SNOMED-CT codes for receiving a surveillance colonoscopy.

In Stage 2, we will submit EHR specifications and claims specifications; the combination of the 2 specifications can be used in registry reporting. The data stream for registries can be claims, EHR or manual data entry.

### Exclusions

**Exclusions** Documentation of medical reason(s) for not recommending at least a 10 year follow-up interval (eg, above average risk patient, inadequate prep)

**Exclusions** Documentation of medical reason(s) for an interval of less than 3 years since the last colonoscopy (eg, last colonoscopy incomplete, last colonoscopy had inadequate prep, piecemeal removal of adenomas, or last colonoscopy found greater than 10 adenomas) OR

Documentation of a system reason(s) for an interval of less than 3 years since the last colonoscopy (eg, unable to locate previous colonoscopy report, previous colonoscopy report was incomplete)

### Exclusion Details

The PCPI methodology uses three categories of reasons for which a patient may be excluded from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For measure 0658, exceptions may include medical reason(s) (eg, above average risk patient, inadequate prep) for not recommending at least a 10 year follow-up interval. Where

The PCPI exception methodology uses three categories of reasons for which a patient may be removed from the denominator of an individual measure. These measure exception categories are not uniformly relevant across all measures; for each measure, there must be a clear rationale to permit an exception for a medical, patient, or system reason. Examples are provided in the measure exception language of instances that may constitute an exception and are intended to serve as a guide to clinicians. For this measure, exceptions may include medical reason(s) (eg, last colonoscopy incomplete, last colonoscopy had inadequate prep, piecemeal removal of adenomas, or last colonoscopy found greater than 10 adenomas) OR

Documentation of a system reason(s) for an interval of less than 3 years since the last colonoscopy (eg, unable to locate previous colonoscopy report, previous colonoscopy report was incomplete).
<table>
<thead>
<tr>
<th>0658 Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients</th>
<th>0659 Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps- Avoidance of Inappropriate Use</th>
</tr>
</thead>
</table>
| examples of exceptions are included in the measure language, these examples are coded and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients’ medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician’s exceptions data to identify practice patterns and opportunities for quality improvement. For example, it is possible for implementers to calculate the percentage of patients that physicians have identified as meeting the criteria for exception. Additional information by data source includes: For claims specifications, a CPT Category II modifier will be reported by the physician to indicate the patient has an allowable exception for the measure. For EHR specifications, we will develop value sets for the examples provided in the measure. | removal of adenomas, or last colonoscopy found greater than 10 adenomas) or system reason(s) for an interval of less than 3 years since the last colonoscopy (eg, unable to locate previous colonoscopy report, previous colonoscopy report was incomplete). Where examples of exceptions are included in the measure language, value sets for these examples are developed and included in the eSpecifications. Although this methodology does not require the external reporting of more detailed exception data, the PCPI recommends that physicians document the specific reasons for exception in patients’ medical records for purposes of optimal patient management and audit-readiness. The PCPI also advocates the systematic review and analysis of each physician’s exceptions data to identify practice patterns and opportunities for quality improvement. Additional details by data source are as follows: For EHR: Patients will be excluded from the denominator if there is documentation of a medical or system reason for performing a colonoscopy within 3 years (less than 3 years) since the last colonoscopy
• Examples of medical reasons include: the last colonoscopy was incomplete or had inadequate prep, there was piecemeal removal of adenomas, or the last colonoscopy found greater than 10 adenomas
• Examples of system reasons include: unable to locate previous colonoscopy report, previous colonoscopy report was incomplete
Value sets for the examples included in the medical or system reasons will be developed to identify patients with allowable exceptions. For Claims: Patients will also be excluded from the denominator if there is documentation of a medical or system reason for recommending a subsequent colonoscopy within 3 years from the current colonoscopy. A CPT Category II code will be reported for patients |
<table>
<thead>
<tr>
<th>Risk Adjustment</th>
<th>0658 Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients</th>
<th>0659 Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps- Avoidance of Inappropriate Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>No risk adjustment or risk stratification Not applicable.</td>
<td>No risk adjustment or risk stratification N/A URL <a href="http://www.ama-assn.org/ama1/pub/upload/mm/370/endoscopy-ms.pdf">http://www.ama-assn.org/ama1/pub/upload/mm/370/endoscopy-ms.pdf</a></td>
<td></td>
</tr>
<tr>
<td>Stratification</td>
<td>We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected.</td>
<td>We encourage the results of this measure to be stratified by race, ethnicity, gender, and primary language, and have included these variables as recommended data elements to be collected. Stratification by insurance coverage (Commercial, Medicare and Medicaid) is recommended by some implementers.</td>
</tr>
<tr>
<td>Type Score</td>
<td>Rate/proportion  better quality = higher score</td>
<td>Rate/proportion</td>
</tr>
<tr>
<td>Algorithm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>To calculate performance rates:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1) Find the patients who meet the initial patient population (ie, the general group of patients that the performance measure is designed to address).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2) From the patients within the initial patient population criteria, find the patients who qualify for the denominator (ie, the specific group of patients for inclusion in a specific performance measure based on defined criteria). Note: in some cases the initial patient population and denominator are identical.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3) From the patients within the denominator, find the patients who qualify for the Numerator (ie, the group of patients in the denominator for whom a process or outcome of care occurs). Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4) From the patients who did not meet the numerator criteria, determine if the physician has documented that the patient meets any criteria for denominator exception when exceptions have been specified (for this measure: medical reason(s)) (eg, above average risk patient, inadequate prep). If the patient meets any exception criteria, they should be removed from the denominator for performance calculation. --Although the exception cases are removed from the denominator population for the performance calculation, the number of patients with valid exceptions should be calculated and reported along with performance rates to track variations in care and highlight possible areas of focus for QI.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>If the patient does not meet the numerator and a valid exception is not present, this case represents a quality failure. Calculation algorithm is included in attachment 2a1.30.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

See sample calculation algorithm attached.
<table>
<thead>
<tr>
<th>0658 Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients</th>
<th>0659 Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps- Avoidance of Inappropriate Use</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Submission items</strong></td>
<td></td>
</tr>
<tr>
<td><strong>5.1 Identified measures:</strong> 0572 : Follow-up after initial diagnosis and treatment of colorectal cancer: colonoscopy 0659 : Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps- Avoidance of Inappropriate Use ACP-018-10 : Endoscopy/Polyp Surveillance: Comprehensive Colonoscopy Documentation 0034 : Colorectal Cancer Screening 0392 : Colorectal Cancer Resection Pathology Reporting- pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade</td>
<td><strong>5.1 Identified measures:</strong> 0034 : Colorectal Cancer Screening 0658 : Endoscopy/Polyp Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients ACP-018-10 : Endoscopy/Polyp Surveillance: Comprehensive Colonoscopy Documentation 0392 : Colorectal Cancer Resection Pathology Reporting- pT category (primary tumor) and pN category (regional lymph nodes) with histologic grade 0572 : Follow-up after initial diagnosis and treatment of colorectal cancer: colonoscopy</td>
</tr>
<tr>
<td>5a.1 Are specs completely harmonized? No</td>
<td>5a.1 Are specs completely harmonized? No</td>
</tr>
<tr>
<td>5a.2 If not completely harmonized, identify difference, rationale, impact: The list of measures above, includes several different populations and capture different elements in the numerator. None of them are aiming to capture the same information as measure 0658. Measures 0572, ACP-018-10, and 0392 actually aim to capture specific elements within the colonoscopy report or pathology report (after colon/rectum resection). Measure 0034 has an entirely different patient population, as it captures patients ages 51-75 only. Measure 0659 focuses on a different patient population, as the patients in 0659 have had a history of a prior colonic polyp in previous colonoscopy findings. The patient population in measure 0659 has a different follow up interval recommendation, according to evidence based guidelines.</td>
<td>5a.2 If not completely harmonized, identify difference, rationale, impact: The list of measures above, includes several different populations and capture different elements in the numerator. None of them are aiming to capture the same information as measure 0658. Measures 0572, ACP-018-10, and 0392 actually aim to capture specific elements within the colonoscopy report or pathology report (after colon/rectum resection). Measure 0034 has an entirely different patient population, as it captures patients ages 51-75 only. Measure 0659 focuses on a different patient population than measure 0658, as the patients in 0659 have had a history of a prior colonic polyp in previous colonoscopy findings. The patient population in measure 0658 has a different follow up interval recommendation, according to evidence based guidelines.</td>
</tr>
<tr>
<td>5b.1 If competing, why superior or rationale for additive value: There are no competing measures.</td>
<td>5b.1 If competing, why superior or rationale for additive value: There are no competing measures.</td>
</tr>
</tbody>
</table>
### Comparison of NQF #0030 and NQF #0098

<table>
<thead>
<tr>
<th>0030 Urinary Incontinence Management in Older Adults - a. Discussing urinary incontinence, b. Receiving urinary incontinence treatment – A patient reported measure</th>
<th>0098 Urinary Incontinence: Assessment, Characterization, and Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older – an administrative measure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Steward</strong></td>
<td>National Committee for Quality Assurance</td>
</tr>
<tr>
<td><strong>Description</strong></td>
<td>This is a patient-reported measure collected through the Health Outcomes Survey with two rates that address management of urinary incontinence in older adults. Discussing urinary incontinence: Percentage of patients 65 years of age and older who self-report having a urine leakage problem in the last six months and who discussed their urinary leakage problem with their health care provider. Receiving urinary incontinence treatment: The percentage of patients 65 years of age and older who self-report having a urine leakage problem in the last six months and who received treatment for their current urine leakage problem.</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Process</td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
<td>Patient Reported Data/Survey Medicare Health Outcomes Survey</td>
</tr>
<tr>
<td><strong>Level</strong></td>
<td>Health Plan, Integrated Delivery System</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Other This measure does not specify a specific setting where care must be provided.</td>
</tr>
<tr>
<td>Numerator Statement</td>
<td>0030 Urinary Incontinence Management in Older Adults - a. Discussing urinary incontinence, b. Receiving urinary incontinence treatment – A patient reported measure</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>a) Discussing Urinary Incontinence: The number of patients who reported having a problem with urine leakage in the past 6 months and indicated they discussed their urine leakage problem with their current provider.</td>
<td>This measure has three rate. The numerator for each of the rates is as follows: (A) Assessment for UI: Patients who were assessed for the presence or absence of urinary incontinence within 12 months (B) Characterization of UI: Patients whose urinary incontinence was characterized at least once within 12 months (C) Plan of Care for UI: Patients with a documented plan of care for urinary incontinence at least once within 12 months</td>
</tr>
<tr>
<td>b) Receiving Urinary Incontinence Treatment: The number of patients who reported having a problem with urine leakage in the past 6 months and indicated they received treatment for their current urine leakage problem.</td>
<td>Urinary incontinence is defined as any involuntary leakage of urine. Characterization of urinary incontinence may include one or more the following: frequency, volume, timing, type of symptoms, and/or how bothersome to the patient Plan of care may include behavioral interventions (e.g., bladder training, pelvic floor muscle training, prompted voiding), referral to specialist, surgical treatment, reassess at follow-up visit, lifestyle interventions, addressing co-morbid factors, modification or discontinuation of medications contributing to urinary incontinence, or pharmacologic therapy.</td>
</tr>
</tbody>
</table>
| Numerator Details | Time Window: The measurement year (one calendar year)  
|---|---|
| 0030 Urinary Incontinence Management in Older Adults - a. Discussing urinary incontinence, b. Receiving urinary incontinence treatment – A patient reported measure | a) Discussing Urinary Incontinence  
Question 3: Have you talked to your current doctor or other health provider about your urine leakage problem?  
Answer="Yes"  
b) Receiving Urinary Incontinence Treatment  
Question 4: There are many ways to treat urinary incontinence including bladder training, exercises, medication and surgery. Have you received these or any other treatments for your current urine leakage problem?  
Answer= “Yes”  
Individuals with dementia and other cognitive disabilities may be unable to answer these questions. To address this limitation, the Health Outcomes Survey allows for a family member or “proxy” to fill out the survey. The survey is mailed to patients with the following instructions: “If you are unable to complete this survey, a family member or “proxy” can fill out the survey about you”  
At the end of the survey, the respondent is asked the following question:  
Q5 = Who completed this survey form?  
Answer = “Person to whom survey was addressed” or “Family member or relative of person to whom the survey was addressed” or “Friend of person to whom the survey was addressed” or “Professional caregiver of person to whom the survey was addressed”  
This information is used to determine if information from proxy respondents is systematically biased or different from patient self-reported data. | Time Window: 1x within measurement year  
The numerator for this measure is based on reporting CPT Category II codes. The codes for each rate numerator are as follows:  
(A) Assessment of UI: 1090F - Presence or absence of urinary incontinence assessed  
(B) Characterization of UI: 1091F - Urinary incontinence characterized  
(C) Plan of Care for UI: 0509F - Urinary incontinence plan of care documented | 0098 Urinary Incontinence: Assessment, Characterization, and Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older – an administrative measure |
<table>
<thead>
<tr>
<th>Denominator Statement</th>
<th>There are two denominators for the rates in this measure. (A) Assessment of UI: All female patients aged 65 years and older who visited and eligible provider in the measurement year (B&amp;C) Characterization and Plan of Care for UI: All female patients aged 65 years and older with a diagnosis of urinary incontinence who visited an eligible provider in the measurement year.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time Window: Measurement Year.</td>
<td>Time Window: 12 month measurement period</td>
</tr>
<tr>
<td>Member choices must be as follows to be included in the denominator: Q1= Many people experience problems with urinary incontinence, the leakage of urine. In the past 6 months, have you accidentally leaked urine? Answer= “Yes” Q2= How much of a problem, if any, was the urine leakage for you? Answer= “A big problem” or “a small problem” (Note: Patients who “not a problem” are not included in the measure denominator).</td>
<td>The denominator for rate (A) Assessment of UI, is based on office visits to an eligible provider. CPT codes are used to identify female patients age 65+ with an office visit to an eligible provider. The denominator for rates (B&amp;C) Characterization and Plan of Care for UI, is based on office visits and a documented diagnosis using ICD-9 codes. (A) Assessment of UI: CPT codes: 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, 99245, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99387, 99397, 99401, 99402, 99403, 99404 (B&amp;C) Characterization &amp; Plan of Care: ICD-9 diagnosis codes 307.6, 625.6, 788.30, 788.31, 788.33, 788.35, 788.37, 788.38, 788.39 AND CPT service codes 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, 99245, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99387, 99397, 99401, 99402, 99403, 99404</td>
</tr>
<tr>
<td>Exclusions</td>
<td>N/A</td>
</tr>
<tr>
<td>Exclusion Details</td>
<td>N/A</td>
</tr>
<tr>
<td>Risk Adjustment</td>
<td>No risk adjustment or risk stratification N/A</td>
</tr>
<tr>
<td>Submission items</td>
<td><strong>5.1 Identified measures:</strong> 0030 : Urinary Incontinence Management in Older Adults - a. Discussing urinary incontinence, b. Receiving urinary incontinence treatment – A patient reported measure</td>
</tr>
<tr>
<td>5a.1 Are specs completely harmonized?</td>
<td>Yes</td>
</tr>
<tr>
<td>5a.2 If not completely harmonized, identify difference, rationale, impact:</td>
<td>UI is defined in both measures as involuntary or accidental leakage of urine. Treatment options for UI across both measures is defined as any of the following: bladder training, pelvic floor muscle training (exercises), surgical treatment (surgery), pharmacologic therapy (medication).</td>
</tr>
<tr>
<td>5b.1 If competing, why superior or rationale for additive value:</td>
<td>Measure 0030 assesses whether the patient believes their urinary incontinence was discussed and treated. This information complements the clinical measure (0098) which assess documentation of management of urinary incontinence in the medical record. Both measures are necessary to allow for continued measurement of this important quality gap at different levels of accountability and using different complimentary data sources. Measure 0098 uses administrative claims coding to determine if UI processes of care (screening, characterization and plan of care) are documented in the medical record for patients who have an in-person visit with an eligible provider. This measure uses codes specifically designed for quality measurement and measures care at the individual provider level. This measure provides detailed information about specific processes of care being provided during a</td>
</tr>
<tr>
<td>5b.1 If competing, why superior or rationale for additive value:</td>
<td>UI is defined in both measures as involuntary or accidental leakage of urine. Treatment options for UI across both measures is defined as any of the following: bladder training, pelvic floor muscle training (exercises), surgical treatment (surgery), pharmacologic therapy (medication). There are several treatment options of UI which are included in measures 0098 which are not included in 0030 because they could not be described in a way which was easy for patients to recall and self-report: prompted voiding, lifestyle interventions, addressing co-morbid factors, modification or discontinuation of medications contributing to urinary incontinence. There are two treatment options which are specific to measure 0098</td>
</tr>
</tbody>
</table>

<p>| NATIONAL QUALITY FORUM | 103 |</p>
<table>
<thead>
<tr>
<th>0030 Urinary Incontinence Management in Older Adults - a. Discussing urinary incontinence, b. Receiving urinary incontinence treatment – A patient reported measure</th>
<th>0098 Urinary Incontinence: Assessment, Characterization, and Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older – an administrative measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>visit with an eligible provider. Unlike measure 0030 it is not susceptible to recall bias and can provide more detailed information. However, this measure has several limitation: (1) documented processes in a medical record are one-sided – they only reflect the provider’s point of view and do not include the patient’s perspective, (2) the codes used for this measure are infrequently reported by providers and this measure excludes individuals who did not see an eligible provider in the previous year and therefore excludes care that may be provided outside of the clinician office such as in the community setting. Measure 0030 uses patient reported information to determine if patients in a health plan received UI processes of care (discuss and treatment). This measure captures the patient perception of care provision which complements the provider point-of-view documented in the medical record. Unlike measures 0098, this measure is not reliant on administrative codes being reported and can be applied to a population of patients regardless of whether they visited an eligible provider in the previous year.</td>
<td>which are not included in 0030 because they refer to a transfer of care to another provider at point in time: referral to specialist and reassess at follow-up visit. Measure 0098 focuses exclusively on women, whereas 0030 refers to all patients. Since women are more likely to experience UI, 0098 was developed to specifically target the care provided to women. The panel of experts who developed 0098 felt the benefits of measurement would be highest for women. Answer for 5b.1 Measure 0098 assesses whether there is documentation in the medical record that older women were assessed for UI, and whether there is documentation in the medical record that those women identified as having UI had their UI characterized and were provided a plan of care to manage their UI. This information complements the survey-based measure (0030) which assess whether patients who experience problems with UI report discussing UI with their health care provider and receiving treatment for their UI. Both measures are necessary to allow for continued measurement of this important quality gap at different levels of accountability and using different complimentary data sources. Measure 0098 uses administrative claims coding to determine if UI processes of care (screening, characterization and plan of care) are documented in the medical record for patients who have an in-person visit with an eligible provider. This measure uses codes specifically designed for quality measurement and measures care at the individual provider level. This measure provides detailed information about specific processes of care being provided during a visit with an eligible provider. Unlike measure 0030 it is not susceptible to recall bias and can provide more detailed information. However, this measure has several limitation: (1) documented processes in a medical record are one-sided – they only reflect the provider’s point of view and do not include the patient’s perspective, (2) the codes used for this measure are infrequently reported by providers and (3) this measure excludes individuals who did not see an eligible provider in the previous year.</td>
</tr>
<tr>
<td>Measure Code</td>
<td>Measure Description</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>0030</td>
<td>Urinary Incontinence Management in Older Adults - a. Discussing urinary incontinence, b. Receiving urinary incontinence treatment – A patient reported measure</td>
</tr>
<tr>
<td>0098</td>
<td>Urinary Incontinence: Assessment, Characterization, and Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older – an administrative measure</td>
</tr>
</tbody>
</table>
## Comparison of NQF C 2052 and NQF C 2063

<table>
<thead>
<tr>
<th></th>
<th>C 2052 Reduction of Complications through the use of Cystoscopy during Surgery for Stress Urinary Incontinence</th>
<th>C 2063 Use of cystoscopy concurrent with prolapse repair surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Steward</strong></td>
<td>American Urological Association</td>
<td>American Urogynecologic Society</td>
</tr>
<tr>
<td><strong>Description</strong></td>
<td>Percentage of SUI surgeries for which cystoscopy was used during the surgical procedure to reduce complications</td>
<td>Percentage of patients that undergo concurrent cystoscopy at the time of surgery for correction of anterior and/or apical vaginal prolapse to check for lower urinary tract injury.</td>
</tr>
<tr>
<td><strong>Type</strong></td>
<td>Process</td>
<td>Process</td>
</tr>
<tr>
<td><strong>Data Source</strong></td>
<td>Administrative claims, Paper Medical Records</td>
<td>Administrative claims, Paper Medical Records Practice Patterns Associated with Surgical Care of Pelvic Organ Prolapse: A Targeted Chart Review</td>
</tr>
<tr>
<td><strong>Level</strong></td>
<td>Clinician : Individual</td>
<td>Clinician : Group/Practice, Clinician : Individual</td>
</tr>
<tr>
<td><strong>Setting</strong></td>
<td>Ambulatory Care : Clinician Office/Clinic</td>
<td>Hospital/Acute Care Facility</td>
</tr>
<tr>
<td><strong>Numerator Statement</strong></td>
<td>Female patients who had SUI surgery for which cystoscopy was used during the surgical procedure to reduce complications</td>
<td>Numerator is the number of female patients where a concurrent intraoperative cystoscopy was performed at the time of surgery for correction of anterior and/or apical vaginal prolapse to check for lower urinary tract injury.</td>
</tr>
<tr>
<td><strong>Numerator Details</strong></td>
<td>Time Window: The numerator will be calculated using CPT codes.</td>
<td>Time Window: Numerator is measured by all women undergoing any vaginal prolapse repair where a concurrent intraoperative cystoscopy was performed. The cystoscopy will be identified by CPT code(s). Any vaginal prolapse repair will be located in the patient’s record using CPT codes for anterior and/or apical vaginal prolapse surgeries.</td>
</tr>
<tr>
<td><strong>Denominator Statement</strong></td>
<td>Female patients who had SUI surgeries (without concomitant surgery for prolapse)</td>
<td>Denominator is the number of female patients undergoing any prolapse repair surgery for correction of anterior and/or apical vaginal prolapse.</td>
</tr>
<tr>
<td><strong>Denominator Details</strong></td>
<td>Time Window: The denominator will be calculated using CPT codes and patient characteristics, such as gender and age (adult patients). Concomitant prolapse surgery includes repair of cystocele, enterocele, rectocele or vaginal vault prolapse or hysterectomy performed due to uterine prolapse.</td>
<td>Time Window: Denominator is identified as the number of female patients undergoing any prolapse repair surgery for correction of anterior and/or apical vaginal prolapse and these female patients will be identified by using CPT codes for these procedures.</td>
</tr>
</tbody>
</table>
### Exclusions

| Exclusions | Documentation of medical reason(s) for not using cystoscopy during SUI surgery (patients for whom the use of a cystoscope may not be appropriate, such as the presence of a new cystostomy repair). The panel noted that endoscopy after a new repair should be cautiously used. Concomitant prolapse surgery is an exclusion. | There are no exclusions from the target population. |

| Exclusion Details | Exclusions will be calculated using CPT codes and patient characteristics, such as gender and age. | There are no exclusions from the target population. |

| Risk Adjustment | N/A | We are not planning to risk adjust this measure. |
| Stratification | N/A | We do not plan to stratify the results. |
| Type Score | N/A | N/A |
| Algorithm | N/A | N/A |
### 5.1 Identified measures:

#### 5a.1 Are specs completely harmonized?

5a.2 If not completely harmonized, identify difference, rationale, impact:

#### 5b.1 If competing, why superior or rationale for additive value:


5a.1 Are specs completely harmonized?

5a.2 If not completely harmonized, identify difference, rationale, impact:

5b.1 If competing, why superior or rationale for additive value: |

As a rule, AUA/ACOG seek to harmonize proposed measures with those currently in use for the same topics. For example, the first of the proposed measures “Complete Workup for Assessment of Stress Urinary Incontinence” describes procedures consistent with common standard practices. In developing the proposed set of measures, extant performance measures were considered and kept in mind but were of limited usefulness because they were designed to apply to urinary incontinence in general and to women over 65 years of age. In contrast, we required measures that focused on the surgical intervention for SUI in particular and included women under 65 year of age who constitute the majority of those affected by SUI.